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Abstract 
 
In this work, a mathematical modelling approach is taken to improve and optimize the 
designs of bioartificial liver (BAL) systems. BALs are an alternative therapy for the 
extremely serious condition of liver failure where liver transplant is currently the only 
viable option.  As yet, large-scale clinical trials have not been successful enough in order 
for BALs to gain regulatory approval. Through the work in this report, it is envisaged that 
BAL design can be improved to the point where they can gain clinical acceptance  
 
One of the main issues in BAL design is the provision of adequate oxygen to the cell mass.  
To this end, a mathematical model to describe oxygen mass transport is developed based 
on the principle of Krogh cylinders. The results of this model are subsequently interpreted 
and presented in Operating Region charts, an image of a parameter space that corresponds 
to viable BAL designs. These charts allow several important design trends to be identified, 
e.g. numerous short and thin hollow fibres are favourable over fewer thicker, longer fibres. 
In addition, it is shown that a physiologically relevant cell number of more than 10% of the 
native liver cell mass can be supported in these devices under the right conditions.  
Subsequently the concept of the Operating Region is expanded to include zonation, a 
metabolic phenomenon where local oxygen tension is a primary modulator of liver cell 
function.  It is found that zonation profiles can be well controlled and under standard 
conditions a plasma flow rate of 185 ml/min to the BAL would distribute the three 
metabolic zones evenly. Finally, the principles of the Operating Region charts and zonation 
are applied to three existing commercial BAL designs; the HepaMate, BLSS and ELAD 
systems. In each case it could be seen that the default designs of each system did not 
present ideal environments for liver cells. Through consideration of zonation profiles, each 
device design and operating parameters could be optimized to produce in vivo-like 
environments. In the case of the ELAD, reducing the plasma flow rate from 500 to 90 
ml/min resulted in a balanced zonation profile. Overall, the work in this report has 
developed and detailed a series of tools that will assist a BAL designer in making judicious 
choices over bioreactor design and operating parameters. As a result, it is hoped that BALs 
can take a step forward towards clinical practice and ultimately saving lives.  
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Chapter 1: Introduction 
 
This report describes a novel, innovative method to improve the design of bioartificial 
livers (BALs). These are devices that seek to sustain a patient suffering from liver failure 
until they can receive a transplant or recover naturally.  Given the scarcity of donor livers 
and the length of transplant waiting lists, BALs could be vital tools to save the lives of 
many people suffering from liver failure.   
 
BALs are extracorporeal devices containing liver cells that support patients whose liver has 
failed, until they can either receive a transplant or spontaneously recover.  Many designs of 
BALs currently exist in various stages of development, some now in the process of or 
having already been evaluated in clinical trials. To date, clinical trials have not 
conclusively shown that BAL therapy can improve survival rates in liver failure patients 
over standard medical therapy.   
 
As BALs have thus far failed to gain regulatory approval and clinical acceptance, a 
theoretical framework to improve and optimize BAL design is outlined in this work. This 
is necessary as adequate oxygen provision to the cell mass is one of the main challenges in 
BAL design. This framework is based on the use of mathematical modelling techniques to 
describe mass transport in BAL.  Initially an extensive literature review has been 
performed in Chapter 2, providing background on liver physiology, liver failure and the 
various methods being developed to treat it. The current key issues facing artificial liver 
support are then outlined. In addition, the various approaches in the past to mathematically 
model hollow fibre bioreactors are summarized, making note of particular cases where 
BALs have been modelled. 
 
As BALs are often based on hollow fibre bioreactors where oxygen depletion is an 
important issue, BAL design must take account of oxygen availability to the liver cell 
mass.  Using various models described in literature as a starting point, a mathematical 
model is developed in Chapter 3 to represent oxygen mass transfer within a hollow fibre 
bioreactor for use as a BAL.  The results obtained from the mathematical model are then 
connected to BAL design.  By also defining two operating constraints on the BAL, useful 
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design trends can be identified.  These constraints can be plotted to define an ‘Operating 
Region’ within which both constraints are satisfied.  These Operating Region charts act as 
visual design tool that allow design parameters to be chosen to create a viable BAL design.  
The sensitivity of the Operating Regions to these parameters can also be established.  In 
addition, the operating constraints allow data regarding maximum cell loadings, minimum 
required plasma flow rates and priming volume of the BAL to be ascertained.  These 
findings allow certain design trends to be identified that point towards better and more 
functional BALs. 
 
In order to increase the effectiveness of any BAL, the cell environment should closely 
match the in vivo conditions they are normally exposed to. As such another objective can 
be defined; the Operating Region concept can be expanded by considering liver 
physiological phenomena, to further improve BAL design.  In particular, gradients of 
oxygen tension within the liver lobule play a large role in defining the functions carried out 
by hepatocytes.  By defining metabolic zones in the liver according to the range of local 
oxygen tension, mathematical modelling can allow the size of each zone within a BAL to 
be determined.  This is seen in Chapter 4.  The size of each zone in the bioreactor will be 
affected by operating and design parameters. A detailed analysis of how each design 
parameter impacts on the zone distribution will be carried out. Similar to the Operating 
Regions of Chapter 3, this will give insight into how more effective BALs can be designed. 
 
Upon establishing a framework of mathematical modelling and BAL design, this 
framework can then be applied to existing BAL systems that are currently undergoing 
development and clinical trials.  Chapter 5 builds on the work of previous chapters by 
applying the same principles to specific BAL designs.  This allows any potential oxygen 
mass transport issues to be identified and possibly remedied through alterations to each 
BAL’s design.   
 
Overall, this work seeks to use mathematical modelling techniques to create a framework 
whereby deficiencies in BAL designs can be identified and more effective designs can be 
found.   Chapter 6 outlines in detail the conclusions that have been made in this work, 
along with the potential impact on the field as a whole.  It is hoped that the work presented 
here and the lessons gained from it will aid the development of more effective BALs. This 
 Chapter 1: Introduction  
 14 
in turn should translate to greater survival rates among liver failure patients, which serves 
to highlight the importance of this work. 
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Chapter 2: Mathematical Modelling of Artificial Livers – 
Literature Review 
 
2.1 Liver physiology 
 
Weighing 1200-1500g in an adult, the liver is the largest internal organ of the human body 
(Fig. 2.1).  It is essential to life and responsible for a myriad of physiological functions. Its 
metabolic activity is such that it produces 20% of the body’s heat at rest  (Scanlon and 
Sanders, 2003).  Its removal in animal models invariably leads to death and liver failure in 
humans is associated with high mortality rates.  The following sections will describe the 
physical structure, functions and physiology of the liver. 
 
 
Figure 2.1: The liver is the only organ in the body to receive a dual blood supply. Blood enters the liver 
through the hepatic artery and portal vein from the small intestine. Diagram adapted from  Merck website 
(Shaffer, 2007)  
 
2.1.1 Structure of the liver 
 
The liver is located below the diaphragm in the upper right and centre of the abdominal 
cavity. At a macroscopic level it can be seen to consist of two large left and right lobes. 
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The structural unit of the liver is the liver lobule, a roughly hexagonal column of liver cells 
about 0.7-2 mm in diameter that surrounds a central vein (Fig. 2.2). The liver receives 
blood from both the hepatic artery and portal vein, the only organ with such a dual blood 
supply.  The branches of these vessels are situated between each lobule (Scanlon and 
Sanders, 2003). Two thirds of the supply is from the hepatic portal vein, originating from 
the small intestine carrying nutrient rich blood.  The rest is oxygenated blood supplied by 
the hepatic artery. The total supply  is approximately 1.5 L/min, a quarter of the resting 
cardiac output  (Telford and Bridgman, 1995, Saxena et al., 2003). The capillaries of each 
lobule are in the form of sinusoids, highly permeable vessels located between each row of 
liver cells. 
 
Figure 2.2: A diagram of the liver lobule (Shipley et al., 2011).  
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2.1.2 Functions of the liver 
 
As stated previously, the liver is responsible for a number of physiological processes in the 
body.  These encompass the regulation of glucose in the blood, synthesis of serum proteins 
and the detoxification of harmful substances to name a few. Some of these processes are 
listed below (Scanlon and Sanders, 2003): 
 
• Detoxification of harmful substances. For example, alcohol is broken down into 
acetate and ammonia is converted into urea   
• Xenobiotic metabolism  
• Regulation of blood glucose levels 
• Synthesis of blood proteins, e.g. albumin, the most abundant plasma protein and 
clotting proteins such as Factor VIII 
• Synthesis of all 12 non-essential amino-acids  
• Bile production for the emulsification of fat in the small intestine 
 
In the case of liver failure in a patient all of these processes will be hampered.  To aid 
survival of the patient some of these functions can theoretically be replaced through 
artificial means. Some of the approaches to achieve this are explained in Section 2.2. 
 
2.1.3 Hepatic microvasculature  
 
The location for the exchange of material between the blood stream and liver cells is the 
sinusoid (Fig. 2.3).  The sinusoids receive venous blood through short venules connected to 
the portal vein, and oxygenated blood through branches of the hepatic arterioles. As these 
vessels have the ability to contract, blood supply to each sinusoid is variable. The sinusoid 
network exhibits a heterogeneity that is determined by its position in the liver. Near the 
portal vein, the network displays a large degree of interconnectivity whereas vessels 
become organised in parallel as they terminate in the central venules.    
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Figure 2.3: A representation of the liver sinusoid. 
 
Each sinusoid vessel has a variable internal diameter of 9-12 µm, the diameter being 
generally smaller at the periportal end of the network. Similar to a normal capillary, the 
vessel wall consists mainly of a single layer of endothelial cells. However, loose 
overlapping of these cells creates a number of fenestrae in the sinusoidal wall.  These 
openings allow contents of the blood (but not platelets or cells) to enter the extraluminal 
space, known the space of Disse, and interact with hepatocytes (Telford and Bridgman, 
1995). Fenestrae account for 6-8% of the sinusoidal surface and are dynamic structures that 
can vary their diameter in response to a number of stimuli, such as blood pressure or 
vasoactive substances. In this way they can influence the plasma levels of larger molecules 
such as cholesterol. The fenestrae also tend to be larger and fewer in number towards the 
periportal end of the sinusoid. 
 
In addition to endothelial cells, which represent 50% of the cells in the sinusoid, three 
other cell types are present. Phagocytotic Kupffer cells form part of the sinusoid lining, fat-
storing stellate cells reside in the space of Disse and pit cells are attached to the luminal 
surface.  Endothelial and Kupffer cells are able to swell and contract selectively to control 
the sinusoid diameter, while stellate cells also display some contractile properties to 
regulate blood flow (McCuskey, 2008). 
 
2.1.4 Hepatocytes and zonation 
  
The liver consists of 80% hepatocytes by cytoplasmic mass (Saxena et al., 2003).  
Hepatocytes are polyhedral and highly polarized, consisting of 2 specialized membrane 
Chapter 2: Mathematical Modelling of Artificial Livers – Literature Review  
 19 
domains. The sinusoidal (or basolateral) membrane faces the sinusoid and is coated with 
microvilli (micron-scaled projections).  The canalicular membrane forms the bile 
canaliculus along with bordering hepatocytes.  These cells are among the most 
metabolically active and versatile within the body, with numerous functions as described in 
Section 2.1.2.  However, heterogeneity exists in the liver so that functions can differ 
between the hepatocytes.  This is known as liver zonation.   
 
The metabolic functions carried out by hepatocytes vary significantly between the different 
regions of the liver lobule.  This is partly due to the availability of substrates within the 
blood, with solute uptake normally being greater in the region of the lobule proximal to the 
hepatic artery and portal vein (Saxena et al., 2003). This is known as the periportal zone.  It 
is also suggested that the functional heterogeneity of hepatocytes is related to differences 
in the sinusoidal fenestrae between the regions of the lobule as described previously 
(McCuskey, 2008). Within the periportal region the capacity for oxidative energy 
metabolism, urea synthesis, bile formation, glucose output and cell protection is greater, 
whereas the capacity for glucose uptake, glutamine formation, and xenobiotic metabolism 
is higher in the perivenous area. The perivenous zone is the region of the lobule closest to 
the central vein of the liver (Jungermann and Kietzmann, 2000, Chan et al., 2004).  This 
zonation of the liver will be an important aspect when considering the design of 
bioartificial livers as it is desired to replace the full spectrum of liver functions within such 
a device.  Oxygen is one of the primary modulators of hepatocyte function (Gebhardt, 
1992, Jungermann and Kietzmann, 2000, Lindros, 1997) and by replicating sinusoid 
oxygenation in vitro, it is hoped this can be achieved.  
 
Mitosis is rare in the adult liver though hepatic cells will divide rapidly to repair a damaged 
liver. The liver has a remarkable ability to regenerate from serious injury. In animal studies 
it has been shown that a full recovery is possible after two-thirds of the organ has been 
removed (Telford and Bridgman, 1995). For humans however, in most cases it not possible 
for a spontaneous recovery to occur after liver failure.  It is this fact that incentivizes the 
development of an effective liver support device; to provide some way to support a human 
liver failure patient until a transplant becomes available or recovery can otherwise occur. 
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2.1.5 Liver failure  
 
In the UK, liver disease is the fifth most common cause of death with up to 13,000 dying 
from liver related conditions in 2005.  Chronic liver disease can progress until liver failure 
occurs, with orthotopic liver transplant currently the only viable treatment.  The waiting 
list for liver transplants is currently between 6-12 months in the UK for low-risk patients 
(British Liver Trust – www.britishlivertrust.org.uk).  Acute liver failure (ALF) can also 
occur in patients who have not previously suffered a chronic liver disease and is the 
primary reason for 9% of liver transplants in Europe in the last 20 years (European Liver 
Transplant Registry – www.eltr.org). 
 
ALF is broadly described as the onset of encephalopathy (general brain dysfunction) 
within 8 weeks of a sudden loss of liver function.  Variations in the definition of ALF exist 
in literature, but it can be considered an umbrella term for liver failure that occurs in 
previously symptom-free patients (i.e. non-chronic).  One type of liver failure often 
referred to in literature is fulminant hepatic failure (FHF), though this can be considered to 
be a particular case of ALF. It is believed that the build-up of ammonia in the blood stream 
caused by liver failure is linked to the hepatic encephalopathy and intracranial 
hypertension which define the onset of ALF (Bernal et al., 2007). There are various causes 
of the disease, with paracetamol overdose being the leading cause in the developed world 
while virus strains, particularly hepatitis, is the leading cause elsewhere (Craig et al., 
2010). 
 
ALF is associated with significant mortality and morbidity with death rates being between 
60-90% (Mareels et al., 2006, de Rave et al., 2002). Despite advances in medicine, 
therapeutic management of ALF is complicated due to the range of causes and differences 
in disease progression (Poyck et al., 2007, Lee et al., 2008).  Again the only effective 
treatment is liver transplant but the scarcity of donor organs leads to long waiting lists.  In 
some cases of ALF the liver can spontaneously recover, negating the need for transplant 
though this occurs in less than 20% of patients (Stadlbauer et al., 2009).  
  
An alternative to organ transplant is the use of engineered liver tissue and research has 
been conducted to this end.  In a recent publication, rat livers were decellularized before 
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being re-seeded with primary rat hepatocytes (Uygun et al., 2010).  It was found that once 
implanted the graft tissue was able to carry out a number of normal liver functions, 
providing a proof of concept.  A similar approach also using decellularized animal livers 
but seeded with human hepatocytes and epithelial cells also yielded positive indicators of 
liver function (Baptista et al., 2009).  In another promising approach, 2d cell sheets of 
hepatocytes were layered to create a three-dimensional construct which was subsequently 
transplanted into mice (Ohashi et al., 2007). However, these approaches to treating liver 
failure still require extensive research before they reach clinical trials and eventual 
practice.  In the short term, extracorporeal devices that can bridge patients to 
transplantation or recovery are being developed (Wigg and Padbury, 2005).  Artificial 
livers can be categorized by whether they use non-biological techniques such as adsorption 
to detoxify the blood, rely on the natural functions of liver cells, or some combination of 
both.  
 
2.2 Artificial livers  
 
2.2.1 "on-biological artificial livers 
 
Various detoxification techniques have been employed in attempts to treat the blood of 
liver failure patients.  Hemodialysis and hemofiltration rely on diffusion and convection 
respectively to remove toxic compounds from the blood, though cannot remove albumin-
bound toxins. Plasma exchange has also been explored, where a patient’s plasma is 
removed and replaced with donor plasma.  However the availability and cost of plasma 
render plasma exchange impractical. In addition these techniques have generally been 
ineffective and had little impact on survival rates (Diekmann et al., 2006, Pryor and 
Vacanti, 2008).  The development of an artificial liver is particularly challenging as unlike 
other organs, the liver controls many aspects of metabolism and physiologic regulatory 
processes (Rozga, 2006). 
 
One of the more advanced artificial liver support systems is the Molecular Adsorbent 
Recycling System (MARS).  This involves hemodialysis of whole blood against an 
albumin dialysate.  Albumin-bound toxins in the blood diffuse across a dialysis membrane 
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to an albumin circuit.  From here the albumin is continuously regenerated by adsorption 
columns and a low-flux dialyser (Fig. 2.4).  In one clinical trial, thirteen patients suffering 
from life-threatening liver failure who had not responded to standard state-of-the-art 
therapy were treated with MARS.  The technology was shown to be safe and nine patients 
recovered (Stange et al., 1999).  More recently, a multicentre clinical trial involving 70 
patients was conducted by Hassanein et al. (2007).  While an improvement over standard 
medical therapy in improving hepatic encephalopathy grade was detected, the length of the 
study meant that an impact on survival rates could not be assessed.  This must be 
considered in future trials in order to fully assess the capabilities of the MARS artificial 
liver.   
 
 
Figure 2.4: A schematic of the MARS artificial liver.  The albumin is regenerated by low-flux dialysis and 
two adsorbers, one of which is charcoal. Diagram taken from Rifai (2008) 
 
A similar system to MARS is Single Pass Albumin Dialysis (SPAD).  Rather than 
regenerating the albumin dialysate it is discarded and fresh albumin added to the circuit.  It 
has been reported that SPAD was significantly more effective than MARS in removing 
ammonia and bilirubin from the blood stream (Sauer et al., 2004).  Another in vitro 
comparison of MARS and SPAD’s ability to detoxify human plasma was carried out by 
Peszynski et al (2001).  Contrary to the above findings it was found that MARS more 
effectively cleared important substances such as bile acids from the blood, while the 
efficacy of SPAD could only be achieved through a dramatic increase in cost.  Without 
further testing and clinical trial data it is difficult to discern SPAD’s effectiveness either 
relative to MARS or absolutely. 
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A variation of the artificial livers described previously is the Prometheus system, 
developed by Falkenhagen et al. (1999).  In this system albumin is separated from plasma 
through a hollow fibre filter before being passed through adsorption columns to remove 
albumin-bound toxins (Fig. 2.5).  The albumin fraction is returned and conventional 
dialysis is used to remove low molecular weight toxins.  The safety of the device was 
demonstrated in a group of 11 patients (Rifai et al., 2003) and larger controlled multi-
centre trials are currently underway (Rifai, 2008). 
 
Figure 2.5: A schematic for the Prometheus artificial liver system.  Albumin from the patient’s blood is 
filtered into the secondary circuit where it is purified directly using an adsorption technique. Diagram taken 
from Rifai (2008). 
 
The above systems have demonstrated the ability to clear toxins implicated in liver failure 
from the blood and improve hepatic encephalopathy grades (Stadlbauer et al., 2008).   
However, as outlined earlier, detoxification is only one of many important functions 
carried out by the liver.  Artificial methods are also non-selective and may remove 
beneficial components from the blood.  As such, the efficacy of these non-biological 
systems is still in question.  An alternative approach is to incorporate liver cells into the 
device in an attempt to more effectively replace the native liver’s function.  These devices 
are known as bioartificial livers (BALs). 
  
2.2.2 Bioartificial livers 
 
The concept of a BAL is to have a liver failure patient’s plasma interact with non-native 
liver cells or tissue in an attempt to replace the native liver’s function until recovery or 
transplant.  A number of attempts have been made to design a bioartificial liver using 
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various membrane configurations and cell lines though only two (the ELAD and 
HepatAssist) have reached phase II FDA human clinical trials (Wigg and Padbury, 2005),  
indicating the difficulty in designing an effective device.  In many devices liver cells are 
contacted with the plasma through hollow fibre modules (Fig. 2.6).  Hollow fibres can 
provide an attachment surface for cells and allow the cells to be protected from fluid shear 
stresses.  In addition the fibres act as an immunological barrier that is important when 
xenogeneic cells are used in the device.  They also resemble the liver lobule and provision 
of this architecture is hoped to maintain hepatocyte differentiation. As hollow fibre 
modules are of interest in this report, several BAL designs that incorporate them will be 
discussed in more detail below. 
 
 
Figure 2.6: A typical hollow fibre bioreactor. This is the Zymax® hollow fibre bioreactor, developed by 
Spectrum Labs (adapted from an image found at www.spectrumlabs.com). Typically, the patient’s plasma 
travels through the fibre lumens while cells reside in the extracapillary space. 
   
Extracorporeal Liver Assist Device  
 
Originally developed by Sussman et al (1991), the latest version of the Extracorporeal 
Liver Assist Device (ELAD) system (Vital Therapies Inc.) contains 440g of immortalized, 
tumour-derived C3A human liver cells inside 4 hollow fibre cartridges (32,000 fibres). 
This is the only current device to exclusively use human cells, although there are concerns 
over the tumorigenic potential of the hepatoma-derived C3A cells (Rozga, 2006).  Prior to 
entering the hollow fibre cartridge, plasma is separated from the blood by ultrafiltration 
and oxygenated (Fig. 2.7).  The plasma passes through a filter before being recombined 
with the cellular fraction of the blood. Previous versions of the ELAD had used whole 
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blood rather than separated plasma.  The plasma and bioreactor are both maintained at 
body temperature.    
 
The ELAD has been tested in 6 human clinical trials to date.  The early trials failed to 
demonstrate any significant survival benefit or improvement in biochemical parameters 
(e.g. ammonia clearance) over control cases (van de Kerkhove et al., 2004). However, in 
the latest clinical trial in China using a modified design, the ELAD was shown to 
significantly improve survival rates in 17 acute-on-chronic liver failure patients 
(Hillebrand et al., 2010).  According to the Vital Therapies website (as of February 2011), 
a large multi-centre trial is ongoing in the USA, Europe and UK in an attempt to replicate 
the results from China. In a poster presentation given in November 2010, significant 
transplant-free survival benefit in 49 ALF patients treated by the ELAD was revealed. 
 
 
Figure 2.7: A schematic for the ELAD system.  The parts labelled ‘ELAD’ are hollow fibre cartridges 
containing human C3A liver cells. From Vital Therapies Inc. (2008). 
 
Bioartificial Liver Support System  
 
The Excorp Bioartificial Liver Support System (BLSS) utilises approximately 100g of 
primary porcine hepatocytes infused into the extracapillary space of a hollow fibre 
cartridge.  In contrast to the ELAD, whole blood perfuses the bioreactor and there is no 
separation stage.  The blood is heated to 37°C and oxygenated before passing through the 
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hollow fibre bioreactor (HFBR).  Nutrient medium is also perfused through the bioreactors 
extracapillary space in order to maintain the hepatocytes (Mazariegos et al., 2002, Patzer et 
al., 2002b).   To date, the largest clinical trial carried out was a phase I trial in 4 patients. 
The safety of the device was demonstrated without any indication of efficacy (Mazariegos 
et al., 2001).  
 
Modular Extracorporeal Liver System  
 
First developed by Gerlach et al. (1994),  the hollow fibre configuration in this system is 
unique in that it consists of three independent hollow fibre bundles woven together.  The 
bundles are used for plasma inflow, plasma outflow, and combined oxygenation and CO2 
removal (Fig. 2.8).  The system is also able to accommodate a large mass of cells: up to 
600g of hepatocytes are immobilized in the extracapillary space, approximately the same 
cellular mass as half of an average adult liver (Sauer and Gerlach, 2002).  In addition to the 
hepatocytes some non-parenchymal cells are present.  Contact between the cells are said to 
help maintain the differentiated state of hepatocytes (Diekmann et al., 2006).  
 
The bioreactor section of the device has been named the ‘CellModule’.  When inoculated 
with primary porcine hepatocytes, treatment with the CellModule was proven to be safe 
with 100% survival rate in 8 patients suffering from ALF and waiting for transplant (Sauer 
et al., 2003). 
 
The Modular Extracoporeal Liver System (MELS) also incorporates non-biological 
techniques to detoxify the blood similar to those described in Section 2.2.1.  As such, the 
MELS can be described as a ‘hybrid’ bioartificial liver.  MELS combines the bioreactor 
described above with SPAD (see Section 2.2.1.) and continuous hemodiafiltration.  In one 
instance the system was loaded with primary human hepatocytes from livers unsuitable for 
transplantation and used to treat 8 patients with liver failure.  All patients underwent 
transplants with a survival rate of 100% after 3 years. As no adverse events occurred, the 
safety of the treatment was demonstrated (Sauer et al., 2002).  
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Figure 2.8: A diagram of the bioreactor used in the MELS. Three fibre networks are woven together, each 
with a different function. Figure adapted from Poyck et al (2007). 
 
TECA Hybrid Artificial Liver Support System 
 
Similar to the MELS, the TECA Hybrid Artificial Liver Support System (TECA-HALSS) 
is also a hybrid liver support system.  In this case the bioreactor is combined with either 
charcoal adsorption or plasma exchange (Xue et al., 2001, Chen et al., 2001).  The 
bioreactor is perfused with plasma and utilises hollow fibres and porcine hepatocytes (100-
300g) as in some of the examples above, however it has one unique feature: rather than 
being immobilized the cells circulate through the extracapillary space along with nutrient 
media (Fig 2.9).  The viability of the hepatocytes is monitored so they can be replaced 
when necessary.  
 
In one clinical trial, 6 liver failure patients were treated with the bioreactor described 
above. In 3 cases, the TECA-HALSS incorporated a charcoal adsorption column while in 
the others 2-3 litres of the patients’ plasma was exchanged for healthy plasma  (Xue et al., 
2001).   The results were promising, with an improvement in neurological function and 
biochemical parameters (e.g. ammonia clearance) in all patients.  In a later trial, the device 
was applied to 15 patients with severe hepatitis. Each device contained in excess of 5 
billion porcine hepatocytes and incorporated plasma exchange before the bioreactor.  In 10 
patients the necrosis of native hepatocytes was halted when the TECA-HALSS was applied 
and they subsequently recovered. One patient underwent liver transplant and survived 
while 4 others died. The treatment was well-tolerated by all patients, displaying the safety 
of the device (Qian et al., 2003).  Further, larger controlled trials will be needed to 
establish the efficacy of the TECA-HALSS although these initial findings are promising.   
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Figure 2.9: A schematic for the BAL section of the TECA-HALSS. The cells and nutrient media circulate 
through the ECS of the hollow fibre cartridge. The non-biological sections are not shown. Taken from Qian 
et al. (2003). 
 
HepaMate (formerly HepatAssist) 
 
Now owned by HepaLife Biosystems, Inc., the HepaMate has been in development since 
the early 90’s (Rozga et al., 1992). It is also a hybrid device, incorporating a charcoal 
adsorption column.  Plasma is separated from the blood and then heated and oxygenated 
before entering the hollow fibre bioreactor. In the initial design of the HepatAssist, 
approximately 7 billion cryopreserved porcine hepatocytes were immobilized on collagen-
coated dextran microcarriers in the extracapillary space (ECS) of the HFBR, which then 
interact with the plasma (Rozga, 2006).  The design has since been updated and according 
to the manufacturers website now incorporates 14 billion porcine hepatocytes. 
 
Under the guise of the HepatAssist, this BAL has had relatively extensive clinical trials 
compared to most artificial livers.  Phase I trials had demonstrated the safety of the device 
and subsequently a large randomized controlled multi-centre trial in the USA and Europe 
took place (Demetriou et al., 2003).  Over 170 patients were enrolled to make it the largest 
bioartificial liver trial to date.  Survival rates for patients treated with the HepatAssist were 
not significantly better when the entire patient group was considered.  However by taking 
several confounding factors into account the patients’ survival rate did significantly 
improve when the HepatAssist was applied. However, given that complex statistical 
analysis had to be performed to arrive at this conclusion, the efficacy of the HepatAssist is 
not entirely clear.  This point of view is echoed by the US Food and Drug Association who 
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deemed that the trial had not successfully demonstrated the efficacy of the HepatAssist 
(Pryor and Vacanti, 2008).     
 
The hollow fibre BALs described above are summarized in table 2.1. Besides these 
designs, there are other BALs which do not employ hollow fibres in a similar manner. An 
example is the Amsterdam Medical Centre BAL developed at the University of 
Amsterdam, in which plasma directly contacts porcine cells in a perfused bed. Hollow 
fibres are used to oxygenate the bioreactor (Chamuleau et al., 1998). Direct cell perfusion 
can enhance mass transfer though fluid shear stresses can adversely affect cellular 
metabolism (Tilles et al., 2001) or cause uneven distribution of cells in the bioreactor (Piret 
and Cooney, 1990). In another example, a bioreactor consisting of two crossed hollow 
fibre bundles has been developed.  The bundles are responsible for medium inflow and 
outflow respectively, while human hepatocytes were cultured between the fibres (De 
Bartolo et al., 2009).   In other designs the cells are seeded within the fibres while flow 
occurs through the extracapillary space (Sielaff et al., 1997).   
 
Apart from hollow fibres, other technologies are being used in bioartificial liver devices.  
One example is the BioEngine where microelectromechanical systems technology is used 
to create a 3D structure designed to mimic a single liver lobule.  The system has been 
tested in rats when seeded with both porcine and C3A cells, where it was found the device 
architecture successfully supported homogenous blood flow through the microchannels 
and the liver cells remained largely viable (Hsu et al., 2010). A fluidised bed bioreactor 
containing C3A cells encapsulated in alginate beads has also been proposed (Kinasiewicz 
et al., 2008a). A review of several novel bioreactor technologies for use in BALs such as a 
microfluidic polymethylsiloxane bioreactor and a microfabricated grooved bioreactor was 
carried out by Yu et al (2009). 
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2.2.3 Key issues in BAL development 
 
Bioartificial livers have been in active development for almost 20 years now, but as yet 
none have successfully demonstrated their efficacy in a large-scale controlled trial.  Trials 
are currently ongoing for several systems, but there are some fundamental issues that 
confound the development of an effective bioartificial liver.  Some of these are technical in 
nature while others are associated with the practicalities of BAL treatment.  Chief among 
these issues is the fact that BAL treatment can be extremely expensive – between $10,000 
and $30,000 per treatment.  Some other more technical concerns are outlined below. 
 
A major issue that remains to be addressed is the source of liver cells. Xenogeneic cells, 
such as porcine hepatocytes are feature in several of the BALs described above.   However, 
a moratorium on xenotransplantation in Europe prohibits the use of these cells (Podger, 
1999). There is also concern over disease transmission from the cells, in particular porcine 
endogenous retrovirus (PERV) though this has not been an issue to date (Kuddus et al., 
2002, Sauer et al., 2003, Morsiani et al., 2002).  Some work has also suggested that 
cytochrome P450 expression in porcine hepatocytes is significantly different than human 
cells, which may limit their clinical applicability (Kleine et al., 2008).  Human cells may 
be ideal however the availability of primary hepatocytes is also limited as healthy organs 
are mainly donated to transplant patients, leaving only discarded grafts as a source.  This 
may be an adequate source of cells for acute liver failure patients (Sauer et al., 2005) but 
could prove to be logistically difficult (Gerlach et al., 2002).  Immortalized human cell 
lines such as the C3A cells in the ELAD are another option, but critical functions such as 
drug and ammonia metabolism are reduced compared to normal cells (Cascio, 2001).  
There is also a small risk that these cells could cause cancer should they somehow reach 
the patients blood stream (Rozga, 2006), though no such incidents have yet been reported.   
A problem associated with all these cell types is the maintenance of their phenotype and 
associated function in vitro.  Human stem cells could provide the answer in the future but it 
is not yet known how to apply them in BAL while maintaining their phenotype (Diekmann 
et al., 2006).  Also of interest are small human hepatocytes, hepatic progenitor cells that 
have the ability to proliferate in vitro and express an array of liver functions (Wurm et al., 
2010, Wurm et al., 2009).  A further option may be the transdifferentiation of pancreatic 
cells; this could provide an autologous cell source for use in a BAL (Shen et al., 2003, 
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Tosh et al., 2002).   The choice of cell for use in a BAL is an important question, but is 
outside the scope of this report. 
 
One aspect of BALs that is also not considered here is the regulatory procedures that must 
be followed in order for the treatment to be endorsed. These procedures vary according to 
the global territory and corresponding regulatory agency, for example the Food and Drug 
Administration in the USA or the European Medicines Agency in Europe.  Each regulatory 
agency has different standards and practices for determining whether a medical product is 
safe and effective.  This evidence is normally obtained through clinical trials, but in the 
case of BALs it can be difficult to organise large trials as they are concerned only with a 
specific liver failure mode, acute or acute-on-chronic liver. As such it can be difficult to 
find the right patients and the trials become lengthy and expensive processes.  The use of 
animal or immortalized cell lines in the devices is also problematic and it is paramount that 
BALs are demonstrated to be safe, with follow-up studies on treated patients to show no 
ill-effects have resulted from BAL treatment.  The use of hollow-fibre cartridges in BALs 
is favourable as regulatory bodies already have experience with them through their use in 
kidney dialysis machines.  More complex BAL designs do exist as described in Section 
2.2.2, though presumably the use of novel bioreactor designs will be met with more 
uncertainty on the part of the regulatory agencies.   
 
Besides cell source and regulatory matters, another issue with BAL design is mass 
transport between the blood/plasma and liver cells (Pless and Sauer, 2005).  In particular, 
oxygen is seen as the most limiting metabolite in HFBR design (Piret and Cooney, 1991).  
Oxygen is even more critical in BAL designs as hepatocytes can have an oxygen 
consumption rate around 10 times greater than most other cell types (Cho et al., 2007). For 
this reason most BAL designs place an oxygenator in the plasma circuit prior to the 
bioreactor. The mass transport of oxygen to the hepatocytes is critical to the efficacy of a 
BAL design and is addressed in this report.  Mathematical modelling has been employed to 
this end, so it is useful to outline the various approaches to this problem seen in current 
literature. 
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2.3 Mathematical modelling of hollow fibre bioreactors 
 
HFBRs have been studied extensively in the past as a means for cell culture.  Only 
relatively recently has there been an interest in expanding their application to tissue 
engineering and artificial organs.  It is thought that by mimicking the microvasculature 
present in natural tissues, cells can be cultured more effectively in vitro.  The hollow fibres 
provide a large surface area for nutrient transport to the growing tissues, similar to 
capillaries in the body.   
 
Quantitative mathematical models for practical applications provide a number of benefits.  
A theoretical framework allows experiments to be guided towards the identification of 
certain key parameters that characterize the process e.g. membrane permeabilities and 
diffusion coefficients.  Once validated, a theoretical model also provides the opportunity to 
optimize a process such as oxygenation of a bioreactor. This can be achieved through 
modelling more quickly and more easily than performing a large number of experiments to 
obtain empirical relationships.  An understanding of the fundamental processes taking 
place and their mathematical representations is necessary for rigorous scientific study of 
practical applications, such as hollow fibre bioreactors (HFBRs). To effectively model the 
HFBR it is necessary to couple various systems of equations describing hydrodynamics, 
mass transfer and substrate consumption kinetics.  A common starting point for many 
HFBR models is the use of Krogh cylinders to describe the system. 
 
2.3.1 Krogh cylinders 
 
Many attempts to model hollow fibre membrane bioreactors make use of Krogh cylinder 
geometry (Fig. 2.10).  This approach is named after August Krogh (1919) who first used 
the model to describe capillaries in animal tissues.  When this principle is applied to 
HFBRs, the entire hollow fibre bundle can be described by a single subunit that consists of 
one fibre surrounded by an annulus of extracapillary space.  This approach assumes that all 
the fibres are identical in terms of properties and internal flow, perfectly straight and 
equally spaced. Additionally, the interstitial spaces between adjacent Krogh cylinders are 
ignored. It is important to note that these are unrealistic or inaccurate assumptions as fibres 
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are often unaligned, moreover the interstitial spaces between fibres may be significant 
when cells occupy them. The use of a more accurate representative elementary volume to 
describe the fibre bundle, as is common in fluid dynamics modelling, may be a means to 
overcome this particular limitation.  Despite this, a number of studies use this method to 
model HFBRs, as will be described below.     
 
Figure 2.10: A cross-section of some Krogh cylinders.  The overall bioreactor can be characterized by 
summing the contributions of an arbitrary number of identical single fibre subunits.  The fibre lumen radius 
Rl , membrane radius Rm and Krogh cylinder radius Re are shown. 
 
2.3.2 Hydrodynamics in a hollow fibre bioreactor 
 
Hollow fibres are characterized by having low aspect ratios, i.e. the fibre diameter is small 
compared to length.  Flow in the fibre lumen is typically of a low Reynolds number and in 
the laminar regime.  As a consequence of these facts the entry length is negligible 
compared to fibre length and so the flow is assumed to be fully-developed on entry to the 
HFBR (Brotherton and Chau, 1996).  A no-slip condition, i.e. zero axial flow velocity at 
the liquid-solid interface, is also assumed for flow at the fibre inner wall. Surface 
wettability and roughness are strong factors in determining slip behaviour, and as in this 
case the interface is porous there may be a degree of slip in practice (Neto et al., 2005). 
Slip effects in hollow fibres of the size normally seen in dialysis applications are generally 
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negligible and can be safely ignored (Belfort and Nagata, 1985, Damak et al., 2004, 
Shipley et al., 2010).  Flow is also normally assumed to be incompressible and Newtonian. 
 
It is also often assumed that the HFBR is operating in a diffusion limited regime and radial 
convection through the membrane is negligible.  In this case laminar flow inside the fibre 
lumen can be described by the Poiseuille equation where flow is solely in the axial 
direction and velocity is a function of radial position (Kundu and Cohen, 2001).  The 
velocity profile is parabolic as seen in Figure 2.11. Equation 2.1 shows how the axial 
velocity u is a function of radial position r. 
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Where ū is the average flow velocity and a is the radius of the fibre. 
 
Figure 2.11: Poiseuille flow in a hollow fibre. 
 
2.3.3 Substrate reaction kinetics 
 
Upon passing through the fibre membrane and coming into contact with cells, oxygen will 
be consumed.  Oxygen uptake and how it is modelled therefore have important 
consequences for the oxygen concentration profiles in the bioreactor and therefore 
appropriate kinetics must be chosen. In general, Michaelis-Menten kinetics are favoured in 
literature to describe substrate uptake in mammalian cells:  
cK
cV
t
c
V
m +
−=
∂
∂
= max  (2.2.) 
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The reaction or consumption rate of the substrate is a function of the maximal consumption 
rate Vmax, the Michaelis-Menten constant Km and the substrate concentration c.  Most 
biological kinetics are found to follow this relationship (Davis and Watson, 1985).  Zero 
and first order kinetics are also common, though these are just extreme cases of Michaelis-
Menten kinetics when substrate concentration is much greater or much smaller than the 
Michaelis-Menten constant Km.  
Zero-order limit: maxVVKc m −≈∴>>  (2.3) 
First-order limit: 
m
m
K
cV
VKc max
−
≈∴<<  (2.4) 
There is significant difficulty in determining the value of the Michaelis-Menten parameters 
necessary to characterise oxygen uptake.  A cell’s metabolism is a function of its 
surroundings, i.e. the culture conditions.    It has been shown that oxygen uptake rate is 
increased in the presence of high ammonia concentrations (Catapano and De Bartolo, 
2002).  A cell’s environment is also important,  such as cell density or whether it is in a 2-
D or 3-D culture (Patzer, 2004). Co-culture with non-parenchymal cells also alters 
hepatocyte oxygen uptake rates (Cho et al., 2007).  The physical and chemical properties 
of the membrane to which the cells are attached is also a factor (De Bartolo et al., 1999).   
Of course, the cell behaviour also differs according to the cell source.  A wide range of 
values for these parameters are seen in literature, as many cell lines and cell environments 
are used. The range of oxygen consumption rates observed has been reviewed by Patzer  
(2004) and examined in Section 4.2.2.  
 
2.3.4 Mass transfer models in hollow fibre bioreactors 
 
Mathematical modelling of HFBRs is complex and various approaches have been used.  
The methods differ through their assumptions and solution procedures.  An overview of 
some of this work is described below, many of which adopt the modelling starting points 
described above.  
 
A general mathematical model for mass transport in a permeable tube with radial 
convection was developed by Ross (1974).  A dilute, Newtonian system with low aspect 
ratio (as is the case for hollow fibres) is assumed with the velocity profile within the fibre 
consisting of a base Poiseuille flow (Fig. 2.7) superimposed with a small axial position- 
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dependent radial convective flow. Ross uses this starting point to develop radial profiles 
for dimensionless concentration and velocity at different axial positions within the tube.  
The results indicate the exit substrate concentration decreases significantly as tube 
diameter, length and membrane permeability increase.   However the solution presented is 
only applicable when there is no substrate uptake in the ECS, as this aspect is not included 
in the model. 
 
An evaluation of the mass transport characteristics in a diffusion-limited hollow fibre 
reactor was carried out by Davis and Watson (1985).  By assuming Poiseuille flow (Eq. 
2.1) inside the fibre lumen and neglecting radial convection, a series of equations to derive 
substrate concentration profiles in the reactor have been presented.  The analysis takes 
account of reduced diffusion through the cells surrounding the hollow fibres and allows 
any form of substrate reaction kinetics in the cell layer.  In order to establish the substrate 
diffusivity in the cell layer, the diffusion coefficient is chosen so that the sum of squares 
error between experimental and predicted substrate conversion is minimized.  The model 
can then be solved numerically to predict substrate concentration within the bioreactor. 
 
Another theoretical analysis of a HFBR was carried out by Schonberg and Belfort (1987).  
Again a Krogh cylinder model is used, although in this case a 4th region that is free of cells 
occupies the outer layer of the cylinder.  The model is simplified into the 1-dimensional 
case by assuming that axial mass transfer can be neglected with a high flow rate in the 
lumen.  Diffusion of glucose and oxygen through the fibre membrane is assumed to be 
unhindered as the membrane is thin and porous and the molecules themselves are small.  
Darcy’s Law is assumed to calculate radial velocity through the membrane and 
cell/enzyme layer.   The authors conclude that radial convection could improve the 
bioreactor’s performance, though this may be complicated by cells blocking the convective 
flux. 
 
Piret and Cooney (1991) analysed oxygen depletion in hollow fibre bioreactors using a 
mathematical model.  In contrast to Schonberg and Belfort (1987), the mass transfer 
resistance of the lumen is included in the model.  In addition, the Krogh cylinder model 
includes a thin low porosity ‘skin’ layer on the lumen-side of the fibre which creates a 
mass transfer resistance in the radial direction.  An order of magnitude analysis was 
performed which led to radial convection being considered negligible. The equations are 
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then solved using a numerical method. Design criteria for the HFBR are then chosen from 
plots of an effectiveness factor defined by oxygen penetration depth into the cell layer. 
Comparison of predicted oxygen limitations to experimental axial cell density profiles led 
to generally good agreement despite uncertainty over the value of model parameters. 
 
A simplified solution for hollow fibre bioreactor design equations was presented by  
Jayaraman (1992).  The analysis is simplified through a number of assumptions such as 
zero radial convective flux and using the first order limit of the Michaelis-Menten equation 
for reaction kinetics. The flow through the lumen is assumed to be Poiseuille flow (Eq. 
2.1). The analysis proceeds by decoupling of the membrane and then the ECS equations by 
treating them as ordinary differential equations.  The lumen equation is solved by 
Kummer’s equation to produce a concentration profile in the lumen.  However, this 
analysis only applies when the fairly restrictive assumptions described above have been 
made and hence the solutions are of limited use.   
 
A comprehensive review of mathematical modelling techniques in HFBRs has been 
written by Brotherton and Chau (1996).  The scope of the review covers Krogh cylinder 
models that consider the HFBR to be either diffusion-limited or convective-flow dominant. 
The authors also describe their own model system, including a cell growth term based on 
Monod kinetics.  The systems of equations are non-dimensionalized and solved 
numerically to create oxygen concentration profiles.  The results indicate that convective 
transport is important to overcome mass transfer limitations that exist during cell growth.  
However, the application of momentum and continuity equations to describe convective 
flow in the ECS must be restricted to when cell density is low.  When the cells reach 
tissue-like density, the ECS should be modelled as a porous medium. In addition to these 
findings, the potential benefits of using alternative flow configurations in the HFBR are 
explored. 
 
Mass transfer characteristics of a diffusion-limited bioreactor have also been studied by 
Willaert et al (1999).  In this article, analytical expressions for the concentration profiles of 
a limiting substrate undergoing Fickian diffusion and cell metabolism are derived.  The 
velocity profile inside the fibre lumen is simplified by assuming plug flow and the radial 
mass transfer resistance in the lumen is ignored by assuming a large axial Peclet number. 
This allows the lumen concentration profile to be found from an ordinary differential 
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equation ODE. Radial profiles for substrate concentration in the membrane and ECS are 
also shown for both the zero and first order limits of Michaelis-Menten kinetics.  The 
influences of diffusion coefficients, membrane thickness and the depth of the ECS region 
are investigated in order to optimize bioreactor performance.   
 
Cabrera et al (2001) have taken a novel approach to modelling of a HFBR.  Their model 
allows analytical solutions to be found for any arbitrary reaction kinetics (e.g. zero order or 
Michaelis-Menten).  Again, a Krogh cylinder model is used and the bioreactor is assumed 
to be diffusion-limited with a parabolic velocity profile in the lumen.  Similar to Jayaraman 
(1992), the membrane equation is integrated to provide modified boundary conditions to 
the non-dimensionalized lumen and ECS equations.  In order to solve these equations the 
appropriate Green’s functions are generated. This method had been used previously to 
solve design equations in dialyzers and packed-bed adsorption.   Numerical algorithms are 
employed to obtain the resulting solutions. The model may be applicable to arbitrary 
reaction kinetics, but is restricted to diffusion-limited bioreactors and is relatively 
complicated to use.  
 
Mathematical modelling software can also be applied to solve mass transport equations in 
HFBR applications. This has been performed extensively by a group at the University of 
Oxford examining HFBRs for use in bone tissue engineering. They employed the 
modelling software, FEMLAB, to model the glucose and oxygen partial differential 
transport equations in a Krogh cylinder representation of a HFBR (Ye et al., 2006, 
Abdullah et al., 2006).  Subsequently the effects on the model due to diffusion at the 
cellular scale (Das, 2007) and component interaction between oxygen and glucose were 
examined (Abdullah and Das, 2007). The modelling software employs a finite-element 
method to solve the relevant systems of partial differential equations.   
 
Table 2.2 summarizes the various approaches described above and how they differ. While 
this is not an exhaustive list of mathematically models of mass transport in HFBRs, it 
appears certain trends such as assuming Poiseuille flow and zero radial convection are 
common.  Besides mathematical models of general HFBRs there have been attempts to 
model HFBRs in the context of a BAL.  As this is a significant part of this work’s goals, 
some of these models are outlined below. 
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Table 2.2: A summary of various approaches to model mass transport in HFBRs. 
Reference Lumen Flow 
Radial 
membrane 
convection 
Reaction 
kinetics 
Model solution 
method 
(Ross, 1974) 
Poiseuille with 
added radial 
component 
Yes None Analytical 
(Davis and 
Watson, 1985) 
Poiseuille No Arbitrary Numerical 
(Schonberg and 
Belfort, 1987) 
Not considered Yes 1st order Analytical 
(Piret and 
Cooney, 1991) 
Plug flow No Zero order Analytical 
(Jayaraman, 
1992) 
Poiseuille No  1st order Analytical 
(Brotherton and 
Chau, 1996) 
Plug flow Yes Zero order Numerical 
(Willaert et al., 
1999) 
Plug flow No Zero/first order Analytical 
(Cabrera et al., 
2001) 
Poiseuille  No General Numerical 
(Abdullah et al., 
2006) 
Poiseuille No 
Zero/first/second 
order 
Finite-element 
software 
   
2.3.5 Mathematical modelling of bioartificial livers 
 
As well as general cell culture applications in HFBRs, various attempts have been made to 
mathematically model BALs in particular.  These cases are directly relevant and inform the 
mathematical modelling carried out in this work.  These works vary in terms of the specific 
systems they are modelling, but also in the modelling assumptions and numerical processes 
that they employ. In some cases experimental data have been obtained in order to validate 
the model or identify model parameters.   
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Giorgio et al (1993) studied the transport of glucose, albumin and fluid in a hollow fibre 
BAL using both a theoretical model and experimental data.  The model is a departure from 
typical Krogh cylinder models in that it considers the fibre bundle as a whole.  It assumes 
that Poiseuille flow is present in the fibres (Eq. 2.1). Two alternative ‘hydraulic 
geometries’ were analyzed. The first configuration considers that the ECS ports of the 
HFBR cartridge are closed.  Hence at low flow rates the pressure in the ECS can be 
assumed to be constant and the average of the bioreactor inlet and outlet pressures.  In the 
second configuration the distal ECS port is connected to the axial outlet of the bioreactor. 
The pressure in the ECS is then constant and equal to the outlet pressure.  This should 
increase transmembrane convective flux relative to the first configuration (due to greater 
transmembrane pressure).  Molecular diffusion is ignored and transport of the solutes is 
assumed to be purely through fluid convection through the membrane.  There are also no 
cells in the model or experiment, so uptake is not included either. Experiments are 
performed to measure transmembrane flux and parameters are estimated by computer. 
Predictions of fluid flux in both hydraulic geometries resemble the experimental results. 
However, the value of the concentration profiles for glucose and albumin is questionable 
given that no cell behaviour is included in the model.  The results indicate that diffusion is 
important at the low flow rates usually seen in BALs.  
 
Subsequent attempts were made to model a BAL in both diffusion-limited and convection 
enhanced modes by a group at the University of Strathclyde (Hay et al., 2000, Hay et al., 
2001).  Both models utilise the familiar Krogh cylinder geometry.  In the case of the 
diffusion limited HFBR, whole blood is assumed to perfuse the device. This necessitates 
the use of the Margaria equation (Eq. 5.5) to represent the oxygen dissociation relationship 
with haemoglobin. Poiseuille flow is assumed in the lumen and the hepatocytes consume 
oxygen according to a Michaelis-Menten relationship.  The parameter values are chosen to 
correspond to the design of the ELAD (see Section 2.2.2) and represent the oxygen uptake 
of different cell lines.   A numerical scheme is used to solve the resulting system of 
equations.   It is concluded that for liver cell lines which consume oxygen at a relatively 
low rate, the cells could be maintained with an adequately permeable hollow fibre 
membrane.  If primary hepatocytes are used, which have higher oxygen uptake rates, the 
HFBR is determined to be inappropriate for use in a BAL as it was not possible to 
adequately oxygenate the cell mass.  However, the paper assumes the inlet partial pressure 
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of blood is 40 mmHg, corresponding to venous blood. It would be possible to increase this 
by oxygenating the blood before it reaches the HFBR.  
 
By opening the ECS ports to reduce pressure in the shell of the bioreactor and switching to 
separated plasma instead of whole blood, a convection-enhanced HFBR was also modelled 
(Hay et al., 2001).  In this case, design parameters were taken from the HepatAssist that 
was undergoing clinical trials at the time. Darcy’s law is used to describe radial flow 
through the fibre membrane and axial flow through the cell region.  The intrinsic 
permeability of the cell-filled ECS is difficult to establish so the model uses a range of 
values (10-12 - 10-8 m2). The radial volumetric flow profile is derived as a second order 
ODE and solved.  Oxygen consumption is then modelled by applying the convective flow 
profile and assuming Michaelis-Menten kinetics in the cell layer.  In this case diffusion of 
oxygen is neglected.  A solution is presented as a first order ODE which is solved through 
a Runge-Kutta numerical method.  Experiments were performed to determine the oxygen 
transfer rates to the cells for plasma containing different oxygen partial pressures. The 
parameter values that resulted in the best fit between the results and theoretical predictions 
were chosen for further modelling. The model predicted that large hypoxic zones would 
exist in the HFBR regardless of whether a high or low value for maximum oxygen 
consumption rate Vmax (Eq. 2.2) was chosen.  However, the authors suggest a lack of 
consistent experimental data may have made any solid conclusions difficult to make.  As 
oxygen is a highly diffusive molecule, neglecting diffusion in the model development is 
incorrect.  This is especially true in the BAL where plasma flow rates are relatively low 
compared to most commercial applications of HFBRs. 
 
Oxygen consumption in a hollow fibre BAL was also investigated by Patzer (2004).  In 
this work, both mathematical modelling and an experimental approach were taken.  The 
mathematical model is a typical Krogh cylinder model, with Poiseuille flow (Eq. 2.1) in 
the fibre lumen and Michaelis-Menten kinetics (Eq. 2.2) describing oxygen uptake.  The 
flow of whole blood through the device is also modelled by using the Hill equation to 
describe oxygen dissociation from haemoglobin.  The system of equations was then non-
dimensionalized to reduce the number of operating parameters from approximately 15 to 8.  
Experiments were also carried out in 11 HFBRs containing freshly isolated porcine 
hepatocytes, each perfused by culture media. As it is not possible to measure spatial 
oxygen profiles within a HFBR, the model could not be validated against experimental 
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results but rather was compared with the model solutions from Hay et al described with 
above.  The model proved to be more conservative than Hay’s when predicting diffusion-
limited regimes.  It was determined that the bioreactor would be diffusion-limited rather 
than kinetically controlled for almost all operating conditions.  The results also appear to 
indicate that the intrinsic, per cell oxygen consumption in the HFBR is a decreasing 
function of the cell density. This may be due to higher cell densities representing a more in 
vivo like environment and hence reduced cell stress rather than diffusional limitations. 
   
A more recent study was carried out by Sullivan et al (2007).  In this work the emphasis 
was placed not only on supplying enough oxygen to the hepatocytes but also to recreate 
liver zonation by representing the spectrum of oxygen tension seen in vivo (see Section 
2.3.4). A Krogh cylinder model was used and the HFBR is assumed to be diffusion-limited 
i.e. no convection across the fibre membranes.  Michaelis-Menten kinetics were used to 
describe the oxygen uptake though they were modified with a parameter that represents the 
fractional cell volume in the ECS.  The ECS oxygen diffusion coefficient was similarly 
modified.  The effect of haemoglobin-based oxygen carriers in the circulating stream was 
examined.  It has been proposed that their presence may alleviate the problems associated 
with oxygenation.  A second convection-diffusion equation was used to describe the mass 
transport of oxygenated haemoglobin within the fibre lumen.  The Adair equation was 
applied to describe the saturation of the haemoglobin as a function of oxygen partial 
pressure.  Unlike previous models that have been described above, in this case the system 
of equations was solved using modelling software, the multiphysics package COMSOL 
3.5a.  In addition to the mathematical modelling, experiments were carried out in order to 
validate the model.  Two HFBRs were set up, one including bovine red blood cells in the 
circulating media to act as oxygen carriers, and the oxygen consumption per cell was 
found.  There was good agreement between the experimental results and model predictions 
for both bioreactors, validating the model.   The model was then used to predict oxygen 
profiles for different operating conditions and in particular, different levels of bovine red 
blood cells.  It was concluded that these oxygen carriers would be able to replicate the 
zonation of the liver within a BAL through provision of an appropriate spectrum of oxygen 
partial pressures.  Without them, it was found that large hypoxic and anoxic regions would 
exist within the BAL.      
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2.4 Summary of Literature  
 
The development of a proven, effective BAL is still a work in progress. Current research 
focuses mainly upon the practical aspects of their development, experimenting with 
different bioreactor configurations and cell lines.  Pre-clinical and small clinical trials have 
shown that BAL treatment is safe and potentially effective, but this success has yet to be 
translated to a large scale trial and so BALs have yet to gain clinical acceptance. Further 
work and research is needed to identify the final form of a successful BAL design. 
 
Current literature disagrees on several aspects of BAL design such as the type and number 
of cells required or the design and operating parameters of the bioreactor (Table 2.1).  
These aspects are crucial to potential effectiveness of any BAL treatment.  However, there 
are also common themes in the literature to suggest a good starting point in improving 
BAL design. For instance, hollow fibre technology has been widely used in the BAL 
designs to this point. Alternatives do exist as described previously at the end of Section 
2.2.2, but it reasonable to assume that hollow fibres are a suitable building block for any 
successful BAL design. They allow for high-density cell culture and provide a physical 
barrier against the patient’s immune system and flow-induced shear stresses. There is also 
the issue over whether to use whole blood or fractionated plasma as the bioreactor 
medium. In general, BAL designs (e.g. the HepatAssist and MELS) have favoured the 
latter. This is likely due to the increased risks of blood clotting or fibre pore blockage 
arising from the use of whole blood, though as a consequence the oxygen-carrying capacity 
of the medium is greatly diminished. The choice of cells has also largely favoured 
xenogeneic types, particularly porcine hepatocytes.  This is largely due to their availability 
and their relatively high functionality compared to immortalized cell lines, though they are 
not without issues relating to safety or regulatory matters. 
 
As stated previously, BAL designs are often based on the use of HFBRs to house the liver 
cells.  There is a wealth of literature describing the use of HFBRs in this manner and in the 
wider field of cell culture.  This includes the use of mathematical models to describe mass 
transport within such systems.  Again, current literature on this topic describes a number of 
different approaches to the problem while reoccurring themes can also be seen (Table 2.2), 
for example Poiseuille flow is a reasonable assumption considering the laminar regimes 
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normally seen in HFBR applications.  In some cases radial convection through the 
membrane is considered while at other times it is ignored.  The choice of BAL design will 
also impact on the modelling parameters used in the model, for example to choice of cell 
type has implications on the oxygen uptake rate in the BAL.  
 
While mathematical models have been used in the context of BALs before, current 
literature lacks methods to cohesively connect the results of mathematical modelling to 
trends in BAL design.  In most cases, the HFBRs in BALs are repurposed from other 
applications such as dialysis. It would appear little thought is given to how the demands of 
a BAL application can be met through specific HFBR design.  Aspects of liver physiology, 
in particular liver zonation, have not been given a great deal of consideration in BAL 
design.  Individual studies have examined zonation, but not in the context of real BAL 
designs.  The use of mathematical modelling combined with identifiable criteria that the 
design should meet in terms of operation and zonation profiles, may allow better designs to 
be created.  
 
2.5 Aims and Objectives 
 
The main aim of this work is to address this gap in the literature, i.e. to use mathematical 
modelling techniques to develop a framework that will rationalize BAL design.  This will 
involve not only developing a mathematical model to describe mass transport in BALs, but 
also subsequently identifying design paradigms that will result in more effective liver 
support.  This will involve considering aspects of liver cell behaviour and physiology and 
relating them to the mathematical model.  The framework that is developed can also be 
used to investigate existing BAL designs to ascertain their likely efficacy. 
 
To achieve this, a number of objectives must be met which are detailed below: 
 
• A mathematical model to describe oxygen transport in hollow fibre BALs will be 
developed based on existing literature.  The model solutions will be obtained using 
the finite-element software package, COMSOL (Comsol Multiphysics). 
• Upon obtaining model solutions, they must be interpreted in such a way as to 
inform better BAL design. This can be done using an ‘Operating Region’ approach 
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where modelling results and operating constraints on the BAL can be combined to 
identify a parameter space that delineates valid BAL designs. 
• To increase the physiological relevance of BAL designs, the concept of zonation of 
liver metabolic functions can be introduced into the design framework. 
• The principles established in this work can be applied to current real-world BAL 
designs as an illustration of both current design deficiencies and the power of the 
theoretical framework in optimizing BAL design.   
 
Overall, this work seeks to develop a rationale based on mathematical modelling to guide 
optimization of BALs. This includes the use of Operating Region charts to locate feasible 
designs and zonation analysis to increase the efficacy of the liver cell population in the 
device.  Upon optimization of the design, the BAL should become a step closer to clinical 
reality.  
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Chapter 3: Operating Regions for Bioartificial Liver Design 
 
3.1 Introduction 
 
The liver is responsible for a multitude of important functions in the body (Section 2.1.2) 
and as a result, liver failure is an extremely debilitating condition.  As the only current 
effective treatment, liver transplantation is beset by a shortage of available organs. 
Bioartificial livers (BALs) have been proposed as an alternative means to treat liver failure, 
particularly acute liver failure (ALF) that is associated with mortality rates as high as 90% 
(de Rave et al., 2002).  However, as described in Section 2.2.3 and 2.2.4, BALs have yet to 
gain clinical acceptance and still face a number of issues that they must overcome to do so.   
 
Chief among these issues is consideration of the mass transport limitations inherent in 
BALs. As BALs are often based on hollow fibre bioreactors (HFBRs) where the cells are 
separated from the medium flow by a membrane, provision of adequate oxygen and 
nutrition to the cells to ensure their survival can be problematic. Oxygen is often 
considered to be the main limiting nutrient in HFBR cell culture due to its low solubility in 
culture medium (Piret and Cooney, 1991).  For BAL applications where patient plasma is 
used rather than haemoglobin-carrying whole blood, this will also be true.  This is 
exacerbated by the relatively large oxygen demand from the metabolically active liver cells 
which consume oxygen up to ten times faster than other cell types (Cho et al., 2007). From 
this it is possible to define one operating constraint on the BAL; sufficient oxygen should 
be supplied to ensure survival of the cells. 
 
In addition to the constraint on oxygen supply, two other main constraints exist on the 
system. In order to be effective, the cartridge must contain a cell loading of 10-40% of the 
liver’s mass (Sullivan et al. 2007) or approximately to 10-40 billion cells for an average 
adult.  The exact figure depends largely on whether the patient has any residual liver 
function. The range of blood/plasma flow rates entering the BAL is also limited; this is 
generally between 100-300 ml/min due to technical constraints relating to red blood cell 
lysis that can occur during plasma fractionation (Pless and Sauer, 2005).  
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In order to design the hollow fibre cartridge within the three constraints outlined above, an 
‘Operating Region’ method is proposed. The concept is similar to a ‘windows of operation’ 
approach; a graphical method for determining operating parameters for a bioprocess 
(Woodley and Titchener-Hooker, 1996, Zhou and Titchener-Hooker, 1999). In windows of 
operation, design constraints are represented by lines on a chart where the axes are design 
variables.  The region or ‘window’ bounded by the constraint lines defines a viable 
parameter space.  This process can also allow optimization, for example through linear 
programming techniques. Operating Regions for the BAL are developed to represent a 
parameter space within which a design is viable.  To do this a model of oxygen transport 
within a diffusion-limited HFBR is developed and subsequently solved. The main 
innovation of this work relative to current literature is that a systematic attempt has been 
made to quantify the effects of BAL design and operating parameters in terms of producing 
viable designs.  Other studies such as those carried out by Hay et al (2000) and Sullivan et 
al (2007) have tended to examine particular designs based on existing BALs and 
bioreactors and modify the operating parameters. The mathematical framework and 
techniques described here serve as a tool to understand the significance of these parameters 
and guide improvement in BAL design.   
 
3.2 Theoretical Aspects 
 
3.2.1 Development of an oxygen transport model 
 
As described in Section 2.3.1 and Figure 2.10, Krogh cylinders (Krogh, 1919) are a 
common starting point in mathematical models of HFBRs (Brotherton and Chau, 1996, 
Piret and Cooney, 1991, Hay et al., 2000, Ye et al., 2006). This approach assumes a 
representative sub-unit of the hollow fibre bundle can be defined by assuming that each 
fibre is identical and arranged in a regular hexagonal pattern (Fig 2.10). The symmetry of 
the system allows the entire HFBR to be considered through a single Krogh cylinder sub-
unit, considerably simplifying the computational effort required.  While in real HFBRs the 
hollow fibres are not ideally arranged, this fact has not prevented the Krogh cylinder 
method being applied in the majority of work on hollow fibre modelling as few alternatives 
exist.  Krogh cylinder models have also been validated against experimental results in 
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previous studies (Patzer, 2004, Sullivan et al., 2007), proving their suitability for this 
model.   
 
Figure 3.1: The use of Krogh cylinders in modelling a hollow fibre BAL. One fibre surrounded by a cell 
layer can describe the entire fibre bundle assuming interstitial spaces between the fibres can be ignored 
(Davidson et al., 2010). 
 
Each sub-unit consists of three domains: the fibre lumen, fibre membrane and an annulus 
of extracapillary space (ECS). In this model of a BAL, the ECS domain is considered to 
consist of a monolayer of cells adherent to the fibre (Fig. 3.1).  This is to reflect the 
arrangement of hepatocytes on sinusoids in vivo, as described in Section 2.1.3. A 
convection-diffusion equation is used to describe the steady-state transport of oxygen in 
the bioreactor (Eq. 3.1), where D is the isotropic diffusion coefficient of oxygen, c is the 
concentration, u is the fluid velocity and V represents the oxygen reaction rate.  The 
equation will take different forms within each region of the sub-unit to represent the 
different mass transport mechanisms in each.   
VccD −∇=∇−∇ .).( u  (3.1) 
The convection-diffusion equation in the lumen domain is given by Equation 3.2. A 
cylindrical axisymmetric coordinate system is used, with radial coordinate r and axial 
coordinate z. The velocity of plasma flow within the lumen is assumed to adopt a 
Poiseuille profile as typically seen in pipe flow, with an average flow velocity defined by 
ū. (Fig. 2.11). The fibre lumen radius is represented by Rl. This is valid here as radial 
convection through the membrane can be assumed to be negligible, with no slip on the 
inner membrane surface (Kundu and Cohen, 2001).  It can also be assumed that entrance 
effects are negligible and the flow is laminar and fully-developed due to typically low 
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Reynolds numbers and the high aspect ratio of the fibres (Brotherton and Chau, 1996).  No 
oxygen generation or uptake takes place in the lumen and hence the reaction term is absent. 
In the following equations the concentration of oxygen is represented by a partial pressure 
pO2 as is convention in the literature. The diffusion coefficient of oxygen in plasma is 
represented by Dplasma.  
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(3.2) 
 
Equation 3.3 describes the mass transport of oxygen within the fibre membrane. As stated 
above, the velocity term is absent as convection is assumed to be negligible in the 
membrane region.  This is valid for membranes of low intrinsic permeability and molecular 
weight cut-offs less than 30 kDa (Brotherton and Chau, 1996) when the bioreactor is 
operated in a closed-shell mode.  The cell layer on the fibre will also impede radial flow. 
These assumptions remove convective flow in the membrane and ECS and hence the BAL 
is diffusion-limited. Due to the relative sizes of pores to oxygen molecules, it has also been 
assumed that oxygen diffusion through the membrane is unrestricted and the diffusion 
coefficient is the same as in the free plasma (Sullivan et al., 2007). 
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Equation 3.4 describes the mass transport of oxygen within the ECS/cell region. Again 
transport is solely by diffusion as there is no fluid flow, however in this case the diffusion 
coefficient represents diffusion through the cells as opposed to plasma (Dhep).  The cells are 
assumed to consume oxygen according to a Michaelis-Menten kinetic relationship. As Vmax 
values are often quoted in literature with units of mol/m3/s, a solubility coefficient α is 
used to convert this into mmHg/s according to Henry’s Law. 
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3.2.2 Boundary conditions 
 
The inlet flow to the fibres is assumed to be plasma separated from venous blood that has 
passed through an oxygenator and contains oxygen at 90 mmHg partial pressure, 
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represented by pO2(in) in Equation 3.5..  This value is representative of normal arterial 
oxygen tension.   
lRrinpOrpO <≤= 0for  )()0,( 22  (3.5) 
Zero axial diffusion can also be assumed at both the fibre inlet and outlet. The 
symmetry at the lumen centre-line can also be represented by a zero-flux condition.  
The length of the fibre is represented by L. 
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The following conditions represent continuity of flux and concentration at the inner and 
outer membrane surfaces respectively.  It is assumed that no partitioning occurs between 
any of the Krogh cylinder regions.  In addition, there is a zero axial flux condition at each 
end of the membrane. The radial positions of the membrane outer surface and Krogh 
cylinder boundary are given by Rm and Re respectively. 
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The remaining boundary conditions represent symmetry at the outer surface of the Krogh 
cylinder and zero flux through the ends of the cartridge in the ECS/cell layer. 
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3.2.3 Modelling parameter values 
 
Table 3.1 lists the various parameters and corresponding values employed in the BAL 
model. These parameters have been chosen to mimic the physiological and physical 
characteristics of the system as much as possible.   
 
Table 3.1: A list of published parameters used in calculations and modelling (Davidson et al., 2010) 
Parameter Value Reference 
Dplasma, oxygen diffusion 
coefficient in plasma 
3 x 10-9 m2/s (Piret and Cooney, 1991) 
Dhep, oxygen diffusion coefficient 
in hepatocytes 
2 x 10-9 m2/s (Piret and Cooney, 1991) 
dcell, approximate cell thickness 25 µm (Sullivan et al., 2007) 
(McCuskey, 2008) 
Vmax, maximum uptake rate of 
oxygen by hepatocytes 
5.87 x 10-3 mol/m3/s (Sullivan et al., 2007) 
(Nyberg et al., 1994) 
Km, Michaelis-Menten constant 3 mmHg (Sullivan et al., 2007) 
(Hay et al., 2001) 
pO2(in), inlet oxygen partial 
pressure of plasma 
90 mmHg (Sullivan et al., 2007) 
α, solubility coefficient for 
oxygen at 37 °C 
 481 mmHg/mol/m3 (Sander, 2007) 
ρarea, surface density of 
hepatocyte monolayer on fibres 
3 x 109 cells/m2 (Sauer et al., 2003) 
Hypoxic limit of oxygen partial 
pressure 
2 mmHg (De Groot et al., 1988) 
 
The diffusion coefficient for oxygen in plasma is assumed to be equal to that commonly 
assumed for cell culture medium (Piret and Cooney, 1991).  Parameters corresponding to 
primary rat hepatocytes have been used to describe the oxygen consumption characteristics 
of the cells, i.e. Vmax and Km.  The maximal oxygen uptake rate, Vmax, is described per unit 
volume of cells under the assumption that the volume fraction of cells in the cell layer is 
unity. The cell layer thickness is chosen to be equivalent to the width of one cell. The 
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anoxic limit is considered to be 2 mmHg as hepatocyte respiration is impaired below this 
oxygen tension (De Groot et al., 1988).   
 
3.2.4 Modelling strategy 
 
The convection-diffusion equation is modelled in a single representative sub-unit of the 
hollow fibre bundle to produce oxygen tension profiles for the BAL.  An axially symmetric 
2-dimensional coordinate system is used to represent the fibre (Fig. 3.2). This model is 
used to determine where the anoxia constraint (pO2 > 2 mmHg) will lie on a chart of fibre 
number " versus lumen radius Rl. At this point it is also useful to define Rm as the sum of 
the lumen radius Rl and the membrane thickness w. Re is then found by further addition of 
the cell layer thickness dcell. 
 
Figure 3.2: Krogh cylinder model as represented within COMSOL (Davidson et al., 2010). 
 
The position of the anoxic zone is defined by the axial distance from the fibre inlet to the 
point where oxygen tension first falls to 2 mmHg.  Based on intuition and initial modelling 
results, it can be assumed this point will fall on the outer boundary of the ECS/cell layer 
(Fig. 3.3). Cells beyond this point are assumed to experiencing anoxia.  This axial distance, 
here named Lhyp, is a function of hollow fibre geometry and operating parameters such as 
plasma flow rate.  When all other variables are constant, Lhyp is a function of the average 
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plasma flow velocity ū.  On this basis the anoxia constraint can be defined as seen in 
Equation 3.18.    
 
In order to solve the above equations, the modelling software COMSOL 3.5a was 
employed. This software allows systems of equations representing different physical 
phenomena to be solved simultaneously, based on finite element methods.  In this case a 
steady-state Convection and Diffusion physics mode is chosen to solve the model 
equations.  The domain of interest (Fig. 3.2) is discretized into a mapped mesh consisting 
of approximately 4000 elements. This is sufficient to ensure that further element 
refinement does not affect the modelling results within 3 significant figures. A mapped 
mesh of rectangular elements is used over a triangular free mesh as the small aspect ratio 
of the fibre causes issues in the free-meshing process. A UMFPACK solver with an 
increased tolerance setting of 10-8 to reflect the non-linearity of the equations is chosen. 
This algorithm tends to perform well over other built-in COMSOL solvers in this case, as 
the iterative solver can often converge to a solution.  
3.3 Results  
 
3.3.1 Model validation and initial results 
 
To show that the model described previously can produce sensible results, it was validated 
against an alternative analytical approach to solving of the model equations.  This process 
is outlined in detail in the work by Shipley et al (2010). The modelling equations were 
solved analytically by initially making a number of simplifying assumptions, such as zero-
order oxygen consumption and a small aspect ratio of order 10-3. Kummer functions were 
then used to define analytical expressions for radial concentration profiles at various axial 
positions along the fibre. When these concentration profiles were plotted alongside 
corresponding profiles produced through the modelling procedure described here, very 
strong agreement was found where concentrations were relatively high. Where 
concentration were relatively low, i.e. the distal end of the fibre, a percentage error of 
3.39% was found between the concentration profiles. It is hypothesized the error largely 
arises due to the Michaelis-Menten constant Km, ignored in the analytical model, becoming 
significant at low oxygen concentrations. These results indicate that the model used in this 
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work is consistent with an analytical approach. The model could be further validated 
through comparison with experimental results. 
 
 
An example of a model solution produced by COMSOL can be seen below (Fig. 3.3). The 
colour map is a representation of the oxygen tension profile in the Krogh cylinder model of 
the BAL. The flow and transport regimes in the cylinder can be characterized by pertinent 
dimensionless numbers. A Reynolds number can be calculated by the expression 
µ
ρ lRu2  , 
where the characteristic length is fibre lumen diameter. Assuming a fluid density ρ of 1000 
kg/m3 and a dynamic viscosity µ of 10-3 Pa.s, Reynolds numbers for the system vary 
between 0.2 and 6, indicating the flow is well within the laminar regime. Axial Peclet 
numbers, given by
LD
Ru
plasma
l
2
, range between 10-2 and 2, indicating that axial diffusion can 
be significant in oxygen transport along the fibre. In a related study (Shipley et al., 2011), a 
dimensionless parameter representing the balance of oxygen consumption versus diffusion 
in the ECS was defined as
)(2
2
inpOD
VR
hep
ml α . In this case it varies between approximately 10-1 
and 1, indicating the process is not controlled by reaction rate. 
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Figure 3.3: Modelling results are used to determine the position of the anoxic zone in the BAL.  The 
colour map represents the profile of oxygen partial pressure in the Krogh cylinder. The modelling 
subdomains are labelled and arrows indicate the directions of oxygen convection and diffusion. The axial 
distance Lhyp indicates the position of the anoxic zone (Davidson et al., 2010).  
 
3.3.2 Relationship between anoxic zone position and flow velocity  
 
Initial modelling results make it clear that for a fibre of specified geometry, i.e. fixed 
lumen radius, membrane and cell layer thickness, Lhyp is directly proportional to average 
flow velocity ū. This can be seen below in Figure 3.4. The corresponding constant of 
proportionality is named khyp (Eq. 3.15).  This finding matches those evident in the 
concentration profiles derived by Willaert et al (1999).  
ukL hyphyp =  (3.15) 
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Figure 3.4: An example of the linear relationship between the axial position of the anoxic zone Lhyp and 
average flow velocity ū.  These results were obtained for a lumen radius of 200 µm and membrane thickness 
of 50 µm.  The R2 value indicates a perfect fit (Davidson et al., 2010). 
 
3.3.3 Operating constraints 
 
Anoxia constraint 
 
Given a total flow rate Q of plasma through the device, average flow velocity ū will be 
inversely proportional to the number of hollow fibres in the bundle as shown below in 
Equation 3.16. 
2
lR"
Q
u
π.
=  (3.16) 
Here " is number of fibres and Rl is the fibre lumen radius. Hence Lhyp is also inversely 
proportional to fibre number (Eq. 3.17). 
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In order that the hepatocytes are not exposed to anoxic conditions, this length Lhyp must be 
greater or equal to the length of HFBR, L. The point at which it equals L represents a 
constraint on the maximum number of fibres in the hollow fibre bundle i.e. the flow rate is 
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only just keeping the cell layer surrounding each fibre above anoxic levels. This constraint 
is described by the equation below (Eq. 3.18): 
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The value of khyp is observed from modelling results and is only applicable to a particular 
geometry of hollow fibre (fixed Rl, w). Given the vast array of combinations of fibre 
geometrical parameters, it is impractical to obtain khyp for each permutation. Instead, an 
empirical relationship between khyp and Rl can be established from modelling results in the 
case of fixed membrane thickness, circumventing this issue. This relationship appears as a 
linear one in the form seen below in Equation 3.19 and Figure 3.5. 
21
BRBk lhyp +=  (3.19) 
Here B1 and B2 are empirical constants whose value depends on the membrane thickness w 
being considered. The R2 value for this relationship is greater than 0.99 within the range of 
interest of lumen radius Rl (100-300 µm).  As a result, the anoxia constraint to be plotted as 
a function of lumen radius with fixed membrane thickness w and plasma flow rate Q (Eq. 
3.20).   
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Figure 3.5:  The relationship between khyp and Rl when all other parameters are constant.  There is a 
clear linear trend (with non-zero intercept) with an R2 value greater than 0.99.  This observation allows 
values of B1 and B2 to be found (Davidson et al., 2010).  
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Cell number constraint 
 
A second constraint on the BAL is defined by the cell population housed in the HFBR – 
the design must support an adequate population of cells in order for the BAL to function 
adequately.  As the model assumes that the hepatocytes form a confluent monolayer on 
each fibre, there must be a minimum amount of fibre surface area to support the desired 
number of cells "cell with cell density ρcell in the bioreactor. For a given fibre design the 
minimum number of fibres is therefore constrained by Equation 3.21. 
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 (3.21) 
Each of the above constraints can be plotted on the same graph of fibre number " versus 
lumen radius Rl to define an ‘Operating Region’ bounded by the curves.  By changing 
parameters such as plasma flow rate Q, membrane thickness w and fibre length L, the 
significance of each parameter in determining the size and position Operating Region can 
be determined. 
 
3.3.4 Operating Region charts 
 
An example of an Operating Region is depicted below (Fig. 3.6), derived from parameter 
values chosen so as to represent a typical design, i.e. a fibre length of 25 cm, membrane 
thickness of 50 µm and plasma flowrate of 200 ml/min. A range of fibre lumen radii from 
100 to 300 µm is considered with a cell number of 10 billion, as this is considered to be the 
minimum required to support liver function.  The chart in Figure 3.6 is used for 
comparison with those created with different parameter values. The size of each Operating 
Region is found through numerical integration and presented in terms of area relative to the 
‘standard’ Operating Region in Figure 3.6. Larger Operating Regions indicate a wider 
range of viable designs and increased margin for error within the model. 
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Figure 3.6:  An Operating Region chart constructed from the following parameter values: L = 25 cm, w 
= 50 µm, Q = 200 ml/min, cell = 1.0 x 10
10
 cells.  The Operating Region is denoted by the shaded region.  
The top curve, representing "max, is due to the anoxia constraint within the BAL and the bottom curve, 
representing "min, is due to the minimum cell number constraint (Davidson et al., 2010). 
 
As fibre length increases the constraint on cell number relaxes while the anoxia constraint 
becomes more restrictive (Fig. 3.7).  Fewer fibres are needed to provide an adequate 
surface area for the cell population to adhere to and hence the Operating Region shifts 
downwards. However, cells at the distal end of longer fibres become more likely to 
experience anoxic conditions.  The Operating Region hence becomes smaller with 
increasing length: the relative sizes are 1.67 and 0.71 for fibre lengths of 15 cm and 35 cm 
respectively, compared to the Operating Region area of Figure 3.6 (where fibre length is 25 
cm). 
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Figure 3.7: Operating regions for a BAL with 2 different fibre lengths: (A) L = 15 cm, (B) L = 35 cm.  
The other parameters are "cell = 1.0 x 10
10 cells, Q = 200 ml/min, w = 50 µm (Davidson et al., 2010).  
 
Figure 3.8 shows that the cell number constraint is unaffected by the plasma flow rate as it 
depends solely on the available fibre surface area.  It is clear however that increasing the 
flow rate causes the anoxia constraint to relax and hence the region becomes larger for 
greater Q, with a relative area of 3.04 for a flow rate of 300 ml/min, the technical upper 
limit (Fig. 3.8B).  A flow rate of 100 ml/min is insufficient to allow a viable Operating 
Region to be defined, as not enough oxygen can be supplied to all the cells i.e. the "min 
curve lies above "max.  
 
 
Figure 3.8: Operating regions with varying plasma flow rate: (A) Q = 100 ml/min (B) Q = 300 ml/min.  
The other parameters are "cell = 1.0 x 10
10 cells, L = 25 cm, w = 50 µm (Davidson et al., 2010). 
 
Figure 3.9 illustrates the fact that the number of cells in the device is only significant in the 
cell number constraint and has no impact on the anoxia constraint.  For a given fibre 
geometry the minimum fibre number "min is proportional to cell number "cell and the cell 
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number constraint becomes more restrictive as more cells are loaded into the device. In this 
case the lower cell number of 5 billion results in an Operating Region 1.26 times bigger 
than the standard Operating Region (10 billion cells). For a cell number of 15 billion, no 
viable designs exist as it is impossible to provide enough oxygen to the cells at the distal 
end of the HFBR at the flow rate considered (Davidson et al., 2010).     
 
Figure 3.9: Operating regions with varying cell number: (A) cell = 5.0 x 10
9
 (B) cell = 15.0 x 10
9. The 
other parameters are Q = 200 ml/min, L = 25 cm, w = 50 µm (Davidson et al., 2010). 
 
Over the range considered of membrane thicknesses considered, the value appears to have 
a small impact upon the Operating Region.  The relative areas are 0.96 and 1.04 for 
thicknesses of 40 and 60 µm respectively (Fig. 3.10). Increasing the thickness restricts 
oxygen delivery to the cells, but also increases the available surface area per fibre for cell 
adhesion. These effects combine to shift the Operating Region to a lower range of fibre 
number while marginally decreasing its size.  
 
 
Figure 3.10: Operating regions with varying membrane thickness: (A) w = 40 µm (B) w = 60 µm. The 
other parameters are Q = 200 ml/min, L = 25 cm, "cell = 10.0 x 10
9 (Davidson et al., 2010). 
 Chapter 3: Operating Regions for Bioartificial Liver Design  
 63 
3.3.5 Minimum flow rate and maximum cell number 
 
For a given fibre geometry, the point at which the anoxia and cell number constraints 
overlap (i.e. "min = "max) can be used to make some important definitions. For a given cell 
number "cell, the value of Q at this point is the minimum flowrate needed to support the 
cells. For a given Q, "cell is the maximum number of cells that can be seeded in the BAL. 
Equations 3.22 and 3.23 describe these relationships below: 
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Interestingly, both of these expressions are independent of the fibre length L. It may be 
counter-intuitive that the maximum number of cells that can be held in the device is 
independent of the fibre (and hence HFBR) length.  However, the increase in length (cells 
per fibre) is offset by the reduction in number of fibres as the flow rate per fibre must 
increase to supply sufficient oxygen to cells at the distal end of the fibres. Hence the total 
number of cells in the BAL is constant for given fibre geometry. 
 
The above expression for "cell(max) can be differentiated using the quotient rule with respect 
to Rl in order to calculate the value of Rl that maximizes the number of cells in the device 
(Eq. 3.24). 
21
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−
=  (3.24) 
The corresponding value of "cell(max) can then be found with this value of Rl.  
Differentiation of Equation 3.22 also results in the same value for lumen radius that will 
minimize the plasma flow required to the device. 
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Figure 3.11:  Minimum flow rate Qmin plotted as a function of lumen radius Rl for three cell 
populations. 
 
The minimum flow rate required is plotted as a function of lumen radius in Figure 3.11, for 
three different cell populations in the device. The values in Table 3.1 are used for 
modelling parameters not otherwise indicated. In each case, a lumen radius of 251 µm 
results in the minimum value of Qmin. The Qmin values are 149, 224 and 298 ml/min for cell 
numbers of 10, 15 and 20 billion respectively. 
 
 
Figure 3.12: Maximum cell number cell(max) plotted as a function of lumen radius Rl for 3 flow rates. 
 
Figure 3.12 displays the maximum cell number Ncell(max) as a function of lumen radius for 
three plasma flow rates.   Ncell(max) is maximized for a fibre radius of 251 µm.  For this 
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radius the BAL can support cell numbers of up to 6.7, 13.4 and 20.1 billion at plasma flow 
rates of 100, 200 and 300 ml/min.   
 
3.3.6 Priming volume 
 
The priming volume of the HFBR is equal to the total intraluminal volume of the fibres.  
As this represents the volume of plasma that is removed from the patient there are benefits 
to safety in restricting its size.  It has been reported that the priming volume for a BAL 
should not exceed 1 litre (Chan et al., 2004). The maximum priming volume in the HFBR 
for a given fibre geometry can be found by considering the number of fibres to be equal to 
"max.  The priming volume can then be found by the following expression: 
LR"V lp
2
max .π=  (3.25) 
By using the definition of "max from Equation (18), the priming volume is given by: 
( )
21
BRBQV lp +=  (3.26) 
 
Figure 3.13: BAL priming volume Vp as a function of lumen radius Rl, for three plasma flow rates. 
 
As can be seen above, priming volume Vp increases linearly with fibre lumen radius Rl as 
expected from Equation 3.26.  Increasing the plasma flow rate Q also causes Vp to increase 
though over the range of Q and Rl modelled, Vp remains below the suggested one litre 
design constraint of the system. 
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3.4 Discussion 
 
Using a 2D Krogh cylinder model it was possible to quantify the constraint that conditions 
in the hollow fibre bioreactor must not become anoxic.  By plotting this constraint 
alongside the constraint for minimum cell number, Operating Regions for the HFBR were 
established.  
 
The length of hollow fibre was varied from 15-35 cm to cover the range of sizes of hollow 
fibre cartridges in haemodialysis.  With longer fibres, the increased surface area allows 
more cell attachment and subsequently fewer fibres are required to meet the cell number 
constraint.  However, the cells at the distal end of the longer fibres are more likely to 
become exposed to anoxic conditions and require a greater flow rate of oxygen-carrying 
plasma, leading to a more restrictive anoxia constraint.  As a result, the Operating Region 
occupies a lower range of fibre number.  The anoxia constraint tightens faster than the cell 
number constraint relaxes, leading to a contraction in the Operating Region for larger fibre 
length.  This indicates that BALs with shorter fibres are ‘safer’ in that errors in the model 
are less likely to result in anoxic conditions. 
 
It is essential to supply enough oxygen to ensure the hepatocytes’ viability in the BAL, 
however it has been reported that blood plasma flow rates are limited to 100-300 ml/min in 
BAL applications (Pless and Sauer, 2005). At the lower end of the scale it becomes 
impossible to support a population of 10 billion hepatocytes while avoiding anoxia. The 
situation is improved with increasing flowrate.  For more cells, it would be expected that 
flow rates close to the maximum will be necessary to provide sufficient oxygen. 
Calculations show that the theoretical maximum cell number that can be supported with a 
flow rate of 300 ml/min is approximately 20 billion cells, or 20% of the cell mass of a 
human adult liver.  This number is found by setting Nmin equal to Nmax and rearranging the 
equation to solve for Ncell.  
 
It has been assumed that the BAL should support 1010 cells as this is often regarded as a 
minimum number of cells that a BAL should contain to be effective (Diekmann et al., 
2006, Strain and Neuberger, 2002). It is possible however for the BAL to support a range 
of cell numbers, the impact of which on the Operating Region was determined.  The results 
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are fairly intuitive, with the cell number constraint steadily becoming more restrictive until 
the design becomes unfeasible.  The anoxia constraint is unaffected by the total cell 
number. This is a result of the Krogh cylinder method where modelling considers only a 
single fibre. Each fibre is treated as being covered in a monolayer of cells, regardless of 
total cell or fibre number in the device. 
 
Finally, the effect of membrane thickness upon the Operating Regions was determined. 
Thicker membranes allowed a greater surface area for cell attachment per fibre, but also 
resulted in greater mass transfer restrictions. In this model, diffusion through the 
membrane is assumed to occur at an equal rate as in plasma.  This effect would be 
exacerbated should oxygen diffusion become restricted through the membrane. The 
Operating Region shifts to occupy a lower range of fibre number and contracts slightly for 
greater membrane thickness, suggesting thinner membranes allow a greater range of viable 
BAL designs.  Thinner membranes also provide greater surface area to volume ratios, 
allowing BALs to contain greater cell numbers per unit volume.  Ultimately the minimum 
membrane thickness will be constrained by practical and mechanical considerations. 
 
In general, most of the Operating Regions are wider at lower fibre lumen radii.  This 
indicates that employing numerous, smaller bore fibres is more likely to result in a viable 
BAL design than fewer, larger diameter fibres. Small fibre diameters also reduce the 
priming volume of the BAL, requiring less blood to be taken from the patient.  The 
Operating Regions indicate that viable designs often require in excess of approximately 
10,000 fibres for intermediate fibre lengths and lumen radii. The upper limit of fibre 
number is more difficult to ascertain and depends in large part upon the device plasma 
flow rate and fibre length.  The charts of minimum flow rate Qmin and maximum cell 
number Ncell(max) suggest that cell populations of over 20 billion can be supported in the 
device for flow rates around the technical limit of 300 ml/min.  This cell number is 
relatively large compared to some existing BAL designs and suggests that effective BAL 
designs may be possible. 
 
Work undertaken by Hay et al. (Hay et al., 2000, Hay et al., 2001) sought to utilize 
mathematical modelling to determine the efficacy of the ELAD and HepatAssist designs of 
the time.  For the ELAD it was concluded that while it may be possible to support liver cell 
lines of low oxygen demand in the system, the hollow fibre design was insufficient to 
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support more metabolically active cell lines such as human primary hepatocytes.  The 
mathematical model used is broadly similar to the one presented in this work, though the 
authors consider maximal oxygen consumption rates (Vmax) of a magnitude greater than 
seen here.  The highest Vmax corresponded to results from a rat hepatocyte monolayer.  2D 
cultures of hepatocytes however are known to have oxygen demands an order of 
magnitude higher than 3D cultures, possibly due to 2D cultures being unnatural and 
causing stress to the cells (Patzer, 2004).  Whole blood was also considered to be the 
perfusate of the system and hence the oxygen-carrying characteristics of haemoglobin were 
also modelled.  This should allow greater oxygenation, though as the blood was considered 
to be venous and not oxygenated prior to entering the hollow fibres, the inlet partial 
pressure of oxygen was only 40 mmHg.   This possibly negated any benefit of including 
the haemoglobin in the model and resulted in poor oxygenation, a view echoed by Moussy 
(Moussy, 2003).  The ELAD design being modelled was considered to contain 20 billion 
C3A cells (an immortalized human cell line derived from HepG2 cells) but was only 
supplied with a flow rate of approximately 170 ml/min. From the results presented here, it 
is clear that this flow rate, coupled with the low inlet pO2, would not be enough to support 
such a large cell population.  Hay et al’s conclusions support the findings in this Chapter, 
while also illustrating a useful feature of the Operating Region concept; it allows 
deficiencies in BAL design to be readily identified.  
 
This work has considered that plasma is used to perfuse the BAL and hence no 
haemoglobin is present.  It can be seen that viable BAL designs could be found in this way.  
Other models consider that either whole blood perfuses the BAL or some concentration of 
haemoglobin-based oxygen carriers (HBOCs) are circulating in the media.  Extensive work 
in this area was carried out by a group led by Andre F. Palmer of the Univerisity of Ohio 
(formerly Notre Dame).    One study sought to model oxygen delivery within a HFBR 
perfused with media containing various different HBOCs (Sullivan and Palmer, 2006). The 
values for inlet oxygen tensions, flow rates and HBOC concentration were varied and it 
was concluded that using oxygen carriers and well oxygenated media would optimally 
oxygenate the bioreactor.  However, that model considered a cell layer approximately three 
times thicker per fibre than seen in this study, and also a higher value for Vmax.  In this case 
each fibre would have to provide oxygen to three times the number of cells and hence 
hypoxia becomes more restrictive.  This would explain the need for oxygen carriers in that 
case, despite similar fibre geometry and flow rates per fibre to this study.   
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The mathematical model presented here is similar to that developed by Sullivan et al. 
(Sullivan et al., 2007), including a number of the parameter values.  Sullivan et al. found 
that HBOCs were necessary in order to provide ideal oxygenation to a HF-BAL.  However, 
as in the last example the cell layer per fibre is approximately 3 times thicker than in this 
work.  By controlling inter-fibre distance, the fibres can be arranged to prevent any more 
than a monolayer of cells attaching to each fibre.  This is similar to the situation in vivo 
where normally a single layer of hepatocytes borders each sinusoid (Telford and 
Bridgman, 1995). This also reduces the oxygen delivering ‘duty’ of each fibre and eases 
hypoxia restrictions. 
 
This work has sought to define a rationale for HF-BAL design, whether it is the HFBR 
dimensions or BAL operating parameters.  To this point there has been little in existing 
literature that makes an argument for using a particular set of design parameters. From this 
work, the use of Operating Region charts allows us to determine the relative importance of 
each geometric and operating variable. Thus viable BAL designs could be produced by 
controlling the operating parameters and hollow fibre characteristics of the device.  It is 
difficult to make direct comparisons between our work and actual BAL designs, as the 
model here may not represent them accurately.  For instance, most designs have a greater 
inter-fibre distance so that more than one layer of cells will surround each fibre.  However, 
the qualitative trends seen here allow some meaningful comparisons to be made. In the 
next Chapter and beyond, the relevance of the Operating Region concept can be increased 
through considerations of liver physiology and differing designs of existing, 
commercialized designs of BALs. 
 
3.5 Conclusions 
 
This work has approached design of a BAL in a novel, systematic manner, to ascertain 
how various design parameters can impact upon device viability.  Whereas studies 
typically focus on existing designs and specifications, ranges of possible designs have been 
considered here to produce a graphical method that allows a prediction over whether a 
BAL design will be functional.  The results also indicate general trends that should be 
followed such as using more fibres of shorter length and smaller diameter which leads to 
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larger Operating Regions.  The model suggests that a cell mass equivalent to 
approximately 10-20% of the adult liver can be supported through judicious choices 
regarding the hollow fibre characteristics and BAL operating conditions. 
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Chapter 4: A Theoretical Approach to Zonation in a Bioartificial 
Liver 
 
4.1 Introduction 
 
In a review of the existing state of BALs in Section 2.2, it became clear that device design 
needs to be improved in order to progress to positive results and clinical acceptance.  
Chapter 3 outlines the concept of Operating Regions, a graphical method to identify viable 
BAL designs and discern favourable design trends.  It was seen that under the right 
conditions, BALs containing therapeutically relevant cell numbers would be viable.  
However, one aspect that has not been considered fully in BAL designs to date and also the 
Operating Region concept is the phenomenon of liver zonation, an important facet of liver 
physiology.  
 
As blood travels through the liver microcirculatory system, or sinusoids, the concentration 
of substrates such as oxygen or hormones will change, causing the signals received by the 
hepatocytes in different regions of the lobule to also differ (Fig. 4.1). As a result 
hepatocyte metabolism and gene expression becomes dependent on the cell’s position 
along the liver lobule. This concept was introduced previously in Section 2.1.4. Liver 
zonation is defined by the heterogeneity in cell function according to position.  The cells in 
the periportal zone, the region close to branches of the portal vein and hepatic artery, differ 
from those in the perivenous zone, which is the region close to the central vein.  
Heterogeneity exists in the presence of enzymes and receptors within the cells (Kietzmann 
and Jungermann, 1996).  Jungermann and Kietzmann (2000) explain the various functional 
differences between the periportal and perivenous zones.  As an example, processes such 
as bile formation and urea synthesis are more prevalent in the periportal zone whereas 
glutamine formation and xenobiotic metabolism take precedence in the perivenous zone. 
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Figure 4.1: Schematic of liver microcirculation and zonation.  The gradient of oxygen tension along the 
sinusoid is a primary modulator of liver function and delineates the three metabolic zones (Davidson et al., 
2010). 
 
Liver zonation is very important in the coordination of liver function. A good illustration 
of this is the liver’s control of blood sugar levels.   In times between meals when blood 
glucose is reduced, periportal hepatocytes begin to release glucose from glycogen which in 
turn is metabolized to lactate in the perivenous cells.  As lactate enters the circulation and 
reaches the periportal zone, enzymes involved in gluconeogenesis are upregulated to 
convert it to glycogen.  When blood sugar levels are high after meals, glucose passes by 
the periportal zone and travels directly to the perivenous hepatocytes where insulin allows 
it to be converted to glycogen for storage (Jungermann and Kietzmann, 2000, Allen and 
Bhatia, 2003, Yu et al., 2009).   
 
Zonation in the liver is generally thought to be primarily modulated by gradients of 
oxygen, hormones and extracellular matrix components in the liver lobule. In particular, 
oxygen is found to be a modulator of both short-term metabolism and long-term gene 
expression in vivo (Jungermann and Kietzmann, 2000, Kietzmann and Jungermann, 1996, 
Gebhardt, 1992, Lindros, 1997).  In one study it has been found that a physiological-like 
oxygen gradient in a flat-plate bioreactor containing rat hepatocytes contributed to 
heterogenous distribution of phosphoeonolpyruvate carboxykinase (PEPCK) and 
cytochrome P450 2B (CYP 2B). The spatial patterning of these proteins in the bioreactor 
was similar to the patterns normally observed in vivo (Allen and Bhatia, 2003).  In a 
subsequent article, rat hepatocytes were co-cultured with non-parenchymal cells in a flat-
plate bioreactor under a physiological oxygen gradient.  The spatial induction of CYP 2B 
and CYP 3A was examined and found to mimic in vivo zonation patterns (Allen et al., 
2005).   These results confirm that oxygen is a primary modulator of liver zonation both in 
vivo and in vitro.  
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Within a bioreactor, oxygen gradients will be determined by aspects such as cellular 
uptake, operating conditions and bioreactor geometry.  In this chapter, it has been 
hypothesized that if bioreactor conditions can be manipulated to produce a physiological 
oxygen gradient, the liver cells will exhibit similar behaviour as in vivo. The Operating 
Region concept and BAL model of Chapter 3 is hence expanded to include definitions of 
distinct liver zones as defined by local oxygen tensions. The size of each zone will vary 
according to the range of viable operating parameters and fibre geometry as defined by the 
Operating Region.  The results show that while the size of each metabolic zone can vary 
over a large range, the distribution of the three metabolic zones could be controlled to an 
extent through BAL design parameters.  In particular cases all of the zones can be made to 
occupy the same volume of the BAL.   In addition, unexpected negative consequences 
arising from over-oxygenation of the cell mass are revealed.   
 
4.2 Theoretical Aspects       
 
The mathematical model employed here to describe oxygen mass transport in the BAL is 
essentially the same as that one outlined in Chapter 3; that is a system of convection-
diffusion equations are solved within a Krogh cylinder representation of a BAL.  Again, 
the finite element-based software COMSOL 3.5a is used to perform the modelling and 
obtain results. However as the Krogh cylinder is of a very high aspect ratio, meshing of the 
structure proved to be problematic in some cases for the work of Chapter 3.  To remedy 
this, it was decided to scale the axial coordinates of the model, in this case by a factor of 
100.  This scaling requires adjustments to be made to the governing equations of the 
system – the diffusion coefficient becomes anisotropic, 104 times smaller in the axial 
direction, and the axial flow velocity is scaled 102 times smaller. The different scaling of 
these parameters results from the power of the length exponent in their units. This 
procedure does not affect the results produced. COMSOL is then able to solve the 
equations numerically to produce oxygen concentration profiles in the Krogh cylinder (Fig. 
4.2).  The dimensionless parameters used to define mass transport characteristics in Section 
3.3.1 take the same values here. 
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Figure 4.2: An example of a model solution found using COMSOL. The colour map defines the local 
oxygen tension and arrows indicate the direction of convective and diffusive flux. The definitions of the three 
metabolic zones have been added to the illustration. 
 
A further enhancement to the modelling procedure outlined to the previous chapter was 
made.  In order to efficiently produce large sets of data where the geometry and operating 
parameters of the BAL are varied, the COMSOL model file is converted to a MATLAB 
function. This is achievable as COMSOL has built-in MATLAB integration.  The inputs of 
the function are the inlet partial pressure of oxygen pO2(in), the maximum oxygen uptake 
rate Vmax, the number of cell layers per fibre CL and the thickness of the fibre membrane w.  
The MATLAB function solves the model over a range of fibre lumen radii and average 
flow velocities using built-in COMSOL algorithms.  The outputs of the function are the 
axial positions of the metabolic zone boundaries Lx as can be seen in Figure 4.2, where the 
subscript x denotes the relevant oxygen tension. The data produced is arranged so that zone 
boundary axial positions are given as a function of average flow velocity ū, for each 
different value for lumen radius Rl.  As in Chapter 3, the empirical relationships found 
allow the boundary position of each metabolic zone to be expressed as a function of fibre 
lumen radius Rl, when all other parameters are held constant.   
 
Again, as in the previous chapter this allows an operating constraint to be defined for the 
BAL; oxygen levels should not fall below 2 mmHg as this would lead to cell necrosis (De 
Groot et al., 1988). This constraint results in a definition of the maximum allowable 
number of hollow fibres in the BAL "max as a function of fibre geometry and a given 
device plasma flow rate Q (Eq. 4.1).  
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In Equation 4.1, M2 and C2 are empirical constants obtained from the modelling results, 
relating position of the hypoxic zone to fibre lumen radius. These parameter names replace 
B1 and B2 of Chapter 3 to allow consistency with the zonation equations below.  The 
subscript denotes the partial pressure of oxygen being referred to, in this case 2 mmHg to 
represent anoxic conditions.  In addition to the oxygen-related constraint, a minimum 
number of hepatocytes are required to achieve the desired device functionality. 
Hepatocytes depend on anchorage to a substrate for maintenance of their function and 
phenotype (Morelli et al., 2007, Lee et al., 2008). This gives rise to a requirement for 
minimum fibre surface area in the device and hence minimum fibre number "min.  This 
constraint can be represented by Equation 4.2. 
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Equation 4.2 differs from the definition of "min in Equation 3.21 with the addition of the 
cell layer number parameter CL.  This reflects the possibility that more than one layer of 
cells can be adherent to each hollow fibre. As in Chapter 3, the number of hollow fibres 
required to produce a viable design is defined by the range between "min and "max.   
 
4.2.1 Zonation equations 
 
As oxygen is a primary modulator of liver zonation, the position of the periportal 
(proximal to branches of the hepatic artery and portal vein), pericentral (central portion of 
the liver lobule) and perivenous (proximal the central vein) zones can be defined by the 
local oxygen tensions.  In vivo, blood enters the liver lobule with an oxygen tension of  60-
65 mmHg which falls to 30-35 mmHg in the perivenous zone (Jungermann and 
Kietzmann, 2000).  This is difficult to replicate, especially when using fractionated blood 
plasma which does not contain haemoglobin and hence has a reduced oxygen-carrying 
capacity.  As a result of this, oxygen levels tend to be higher at the inlet and lower at the 
outlet of the bioreactor than in the liver lobule.  This wider oxygen range still tends to 
produce in vitro zonation similar to the native liver lobule (Allen et al., 2005, Allen and 
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Bhatia, 2003).  The periportal zone has been defined to exist where oxygen tensions are 
above 60 mmHg, the pericentral zone occupies the range from 35 to 60 mmHg and the 
perivenous zone experiences oxygen tensions below 35 mmHg (Chen and Palmer, 2009, 
Sullivan and Palmer, 2006, Sullivan et al., 2007).  The same definitions will be applied 
here and can be seen in Figure 4.2. 
 
In Chapter 3, the position along the hollow fibre that marked the onset of anoxia was 
related to plasma flow rate by a proportionality coefficient k.  The position of the 
boundaries of each metabolic zone can be found in the same way.  For a viable design that 
satisfies the constraints of Equations 4.1 and 4.2, the approximate fractional size of each 
metabolic zone is given below in Equations 4.3 to 4.7. The fractional size of each zone is 
assumed to be equal to the proportion of the axial distance between its boundaries to the 
total fibre length (Fig. 4.2). 
 
Periportal zone size 
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In Equation 4.3, fpp is the fractional size of the periportal zone, L60 is the axial distance 
along the fibre to the boundary of the periportal zone (60 corresponding to 60 mmHg 
oxygen tension) and L is the length of the fibre. The zone boundaries in the model will be 
curved, and hence the calculation here that uses the proportion of L60 to L will be an 
approximation. The axial distance to the zone boundary is proportional to the flow velocity 
ū. The proportionality coefficient k60 can be represented as a linear function of fibre lumen 
radius Rl with a slope of M60 and an intercept of C60.  This relationship was established in 
Chapter 3 in finding the position of the anoxic zone in the fibre (Fig. 3.5). The number of 
fibres in the bundle is given by ", which can vary between the maximum and minimum 
constraints (Eqs. 4.1 and 4.2).  The principle used here to define the periportal zone size in 
Equation 4.3 is also applied to define the pericentral and perivenous fractional zone sizes 
in Equations 4.4 - 4.8. 
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Pericentral zone 
 
If the exit oxygen partial pressure is less than 35 mmHg, the perivenous zone will exist in 
the BAL. In this case the pericentral zone size is given by Equation 4.4: 
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If this is not the case then Equation 4.5 is used: 
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L
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Perivenous zone 
 
If the exit pO2 is less than 35 mmHg and the perivenous zone exists, its size is given by 
Equation 4.6: 
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Conversely if the exit oxygen partial pressure is above 35 mmHg, the perivenous zone size 
is absent (Eq. 4.7): 
0=PVf  (4.7) 
From the definition of the zone sizes in Equations 4.3 – 4.7, it is possible to find the device 
flow rate Q or fibre number " that results in the periportal and perivenous zones occupying 
the same volume.  These parameters are named Qeq and "eq respectively as they represent a 
configuration where periportal and pericentral hepatic functions have equal prevalence.  
Whether this is actually an optimal situation for the BAL is a point discussed later.  By 
rearranging Equations 4.3 and 4.6 such that the periportal and perivenous fractional zone 
sizes are equal, the equation can be solved for Qeq and "eq (Eqs. 4.8 and 4.9): 
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If Qeq is below 300 ml/min i.e. the technical upper limit of plasma flow rate in BAL 
applications (Pless and Sauer, 2005), or Neq is within the confines of the Operating region 
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then a BAL can designed where the periportal and pericentral metabolic zones occupy an 
equal amount of the cell volume.     
 
4.2.2 Parameter values  
 
As in Chapter 3, modelling parameter values were chosen so as to represent typical hollow 
fibre BAL systems.  The ranges of fibre lumen radius Rl and length L are representative of 
common hollow fibre geometries.  The range of plasma flow rate Q was determined by two 
factors; the maximum flow rate due to technical reasons (300 ml/min) and the minimum 
flow rate (200 ml/min) that can produce adequately sized Operating Regions as observed 
in the previous chapter. A range of cell numbers "cell  was chosen around an intermediate 
value of 10 billion cells, this number is generally considered the minimum required for a 
functional BAL (Sullivan et al., 2007, Allen et al., 2001).  The inlet partial pressure of 
oxygen pO2(in) was varied between 70 and 110 mmHg. The lower end of the scale is 
similar to physiological arterial oxygen tension while the upper end approximately 
represents maximum oxygen solubility in plasma at 37° C.  The value for maximal oxygen 
uptake rate Vmax was equal to a value reported for hepatocytes in a similar system (Nyberg 
et al., 1994). This value falls within the range of oxygen consumption rates (OCR) reported 
for 3D hepatocyte cultures and summarized by Patzer (2004). The range for Vmax reported 
by Patzer was replicated in this study. The oxygen consumption rates in units of mol/cell/s 
were converted by assuming that each cell had the same volume as a sphere of 25 µm 
diameter.  At the lower end of the scale Vmax was equal to 2.93 µM/s and at the upper limit 
was equal to 11.25 µM/s.  As hepatocytes form a layer one or two cells thick around each 
sinusoid (Telford and Bridgman, 1995), the effect of  having a double cell layer (CL = 2) 
around each hollow fibre was studied. 
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Table 4.1: Parameter values considered in the model, with references for the ranges 
Parameter Studied range Standard Value References 
Fibre lumen radius 
Rl 
100 – 300 µm 200 µm (Hay et al., 2000, 
Sullivan et al., 
2007, Hay et al., 
2001)  
Fibre length L 15 – 35 cm 25 cm (Moussy, 2003, 
Hay et al., 2000) 
Plasma flow rate Q 200 – 300 ml/min 250 ml/min (Pless and Sauer, 
2005) 
Inlet partial pressure 
of oxygen pO2(in) 
70 – 110 mmHg 90 mmHg (Sullivan et al., 
2007) 
Maximal oxygen 
uptake rate Vmax
 
2.93 – 11.25 µM/s 5.87 µM/s (Sullivan et al., 
2007, Patzer, 2004) 
BAL cell population 
"cell 
7.5 – 12.5 billion 10 billion (Allen et al., 2001) 
Cell layer number CL 1-2 1 (Saxena et al., 
2003) 
 
4.3 Results 
 
To illustrate how zonation profiles can be incorporated into the concept of Operating 
Regions, the standard design parameters of Table 4.1 were used to construct an Operating 
Region chart (Fig. 4.3).  In Figure 4.3A, the maximum fibre number "max limit defines how 
many fibres can be contained within the BAL while maintaining adequate hepatocyte 
oxygenation.  The minimum fibre number "min limit defines the minimum number of fibres 
required to provide the BAL with an adequate cell population. Figure 4.3B illustrates how 
the zones are distributed in a BAL being operated under the same conditions for a fibre 
lumen radius of 200µm.  The chart shows the fractional zone sizes at the limits of fibre 
number ("min and "max) and hence the possible extremes of zonal distribution while staying 
within the Operating Region.   The effects of varying the operating and design parameters 
on the zone distributions are explored in the Section 4.3.1.  In addition, values of plasma 
flow rate Qeq that minimize the difference in size of the periportal and perivenous zones 
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(Eq. 4.8) are plotted where possible.  The value of fibre number that gives an equal 
distribution of the periportal and perivenous zones, "eq is also shown (Eq. 4.9). This is 
done by adding an extra line to the Operating Region charts in each case.  
 
Reynolds and Peclet numbers can be calculated to describe the characteristics of mass 
transport in the model. Reynolds number, when calculated as described in Section 3.3.1, 
ranges approximately between 0.2 and 6. This is confirmation that plasma flow in the fibre 
is laminar.  Peclet number again varies between approximately 10-2 and 2, showing that 
axial diffusion of oxygen in the lumen can become significant. A parameter relating 
oxygen consumption to diffusion in the cell layer, defined as 
)(2
2
inpOD
VR
hep
ml α , varies 
approximately between 0.1 and 1, showing that neither diffusion or reaction mechanisms 
are particularly dominant. 
 
 
Figure 4.3: (A) Operating region chart produced using the parameters of Table 4.1 (B) The 
distribution of the metabolic zones at both extremes of the Operating Region, for a fibre radius of 200 
µm.   
  
4.3.1 Zonation profiles for varying fibre geometry 
 
The significance of the hollow fibre lumen radius to the zone distribution in the BAL can 
be observed in Figure 4.4.  The influence appears to be minimal with the distribution 
changing little over the range of fibre radii considered (Fig. 4.4A). When operating with 
the plasma flow rate Qeq (Fig. 4.4B), the periportal and perivenous zones each occupy 34.1, 
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33.2 and 32.9% of the cell volume for lumen radii of 100, 200 and 300 µm respectively. 
The Operating Region for various lumen radii can be redrawn using the standard 
parameters of Table 4.1 with an added line to represent the fibre number that gives rise to 
an equal distribution of the periportal and perivenous zones (Fig 4.4C). The "eq line passes 
approximately through the centre of the Operating Region. 
 
 
Figure 4.4: Charts describing the influence of varying lumen radius on zonation profiles. (A) 
Distribution of metabolic zones in the case of (I) Rl = 100 µm, (II) Rl = 200 µm and (III) Rl = 300 µm (B) The 
flow rate required to produced balanced periportal and perivenous zones Qeq is shown as a function of fibre 
number (C) The Operating Region with an additional "eq line to represent the design configuration where the 
periportal and perivenous zones occupy equal portions of the cell mass. 
 
Fibre length does not have any influence upon zone distribution and hence the zone 
distribution chart is not shown.  While this may seem counterintuitive, changes to fibre 
length are offset by the corresponding changes in Nmin and Nmax such that the effect is 
cancelled out.  However, fibre length does have an influence on the plasma flow rate 
needed to balance the metabolic zone distribution (Fig. 4.5A).  In each case of fibre length, 
a minimum flow rate of 132 ml/min will cause the periportal and perivenous zones to each 
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occupy 33.2% of the cell volume.  An Operating Region can also be constructed to show 
how "eq varies as a function of fibre length. The value of "eq is approximately half way 
between the fibre number constraints "min and "max. 
 
Figure 4.5: Charts describing the influence of varying fibre length on zonation profiles. (A) The Qeq plot 
for 3 values of fibre length L: 15, 25 and 35 cm.  As the fibre length does not affect the distribution of zones 
at the "min and "max design limits that chart is not shown. (B) The Operating Region, redrawn to show the 
fibre number constraints and "eq line as a function of fibre length using a fibre lumen radius of 200 µm 
4.3.2 Zonation profiles for varying plasma flow rates 
 
Figure 4.6A shows how varying plasma flow rates in the BAL affect the relative size of 
each metabolic zone.  The zone distribution is unaffected if the BAL is operated on the 
upper limit constraint i.e. the number of fibres " is equal to "max and oxygen levels are just 
barely sufficient.  In this case the periportal, pericentral and perivenous zones occupy 26.8, 
27.1 and 46.0% of the cell volume respectively.  At the other extreme where " = "min, 
increasing flow rate tends to increase the relative sizes of the periportal and pericentral 
zones.  The periportal zone occupies a maximum of 53.8% of the BAL for the highest flow 
rate while the perivenous zone disappears entirely in this case.  Operating Regions were 
drawn for the cases where the plasma flow is 200 or 300 ml/min (Fig. 4.6B and 4.6C). The 
relative position of the "eq line within the Operating Region changes in each case, initially 
lying close to the "min constraint for Q = 200 ml/min and then moving towards the "max 
constraint at the higher flow rate. 
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Figure 4.6: Visualization of the influence of plasma flow rate on zonation profiles.  (A) Distribution of 
metabolic zones in the case of (I) Q = 200 ml/min, (II) Q = 250 ml/min and (III) Q = 300 ml/min. The zone 
distribution is unaffected by Q when operating on the "max limit and hence the bar is drawn only once.  (B) 
The Operating Regions when Q = 200 ml/min and (C) 300 ml/min is drawn with the "eq line added. 
 
4.3.3 Zonation profiles for varying inlet oxygen tension 
 
The distribution of each metabolic zone under differing inlet oxygen tensions can be seen 
in Figure 4.7A.  At a lower level of 70 mmHg the perivenous zone is largest, occupying 
between 44.8 - 58.3% of the cell volume depending on the number of fibres. When a 
higher oxygen tension of 110 mmHg is employed, the perivenous zone shrinks in size and 
when the fibre number is minimum it disappears entirely.  The periportal zone dominates 
in this situation, occupying 80.0% of the cell volume. When using an inlet oxygen partial 
pressure of 70 mmHg the flow rate required to produce equal periportal and perivenous 
zones is above 300 ml/min within the fibre number constraints and therefore it is 
impossible to achieve an equal zone distribution in the BAL for this partial pressure. For a 
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given number of fibres in the BAL, a higher partial pressure of oxygen allows equal zones 
to be achieved (33.2% each for 90 mmHg, 38.9% each for 110 mmHg) with a lower device 
flow rate (Fig. 4.7B). A minimum flow rate of 122 ml/min can create an equal zone 
distribution in the case of pO2(in) = 110 mmHg.  Figures 4.7C and 4.7D show how the 
inlet oxygen tension affects the position of the equal zones fibre number "eq within the 
Operating Region charts.  With inlet oxygen tension set to 70 mmHg, the "eq line lies 
below the Operating Region whereas for 110 mmHg oxygen tension it is above the 
Operating Region.  In each of these cases it is hence impossible to obtain equal periportal 
and perivenous zones while satisfying the operating constraints of the BAL.   
 
 
 
 
Figure 4.7:  The effects of varying inlet oxygen partial pressure on zonation. (A) Distribution of 
metabolic zones in the case of (I) pO2(in) = 70 mmHg, (II) pO2(in) = 90 mmHg and (III) pO2(in) = 110 
mmHg.  (B) In the Qeq plot, a pO2(in) value of 70 mmHg required a Q value greater than 300 ml/min to 
produce equal periportal and pericentral zones and hence this was not included in the chart. (C and D) The 
Operating Regions constructed for values of pO2(in) = 70 mmHg and 110 mmHg respectively, with an added 
line to represent "eq. 
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4.3.4 Zonation profiles for varying cell number 
 
As was the case for flow rate, the cell number "cell does not affect the distribution of zone 
sizes when the BAL is operated on the Nmax constraint (Fig. 4.8A). However, when the 
BAL is operated with the minimum allowable number of fibres, the perivenous zone 
increases from 0 to 27.8% of the cell volume when the highest cell number is inoculated.   
To produce a zone distribution where the periportal and perivenous zones both occupy 
33.2% of the cell volume each, the BAL should be operated with a plasma flow rate Qeq, 
given in the chart as a function of fibre number (Fig. 4.8B).  The contour is unaffected by 
the cell population size, though the lower limit of fibre number "min will change. In Figures 
4.8C and 4.8D the positions of the "max and "eq lines are unchanged in the Operating 
Regions for either of the cell numbers "cell considered, 7.5 and 12.5 billion respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4: A Theoretical Approach to Zonation in a Bioartificial Liver 
 86 
 
 
Figure 4.8: Charts describing the influence of cell number on zonation. (A) Distribution of metabolic 
zones in the case of (I) "cell = 7.5 billion, (II) "cell = 10 billion and (III) "cell = 12.5 billion cells. (B) Qeq is 
plotted up to a limit of 300 ml/min for each of these "cell values and the lines produced are co-incident.  The 
vertical dash lines indicate the position of "min for each of the three cases. (C and D) Operating Regions are 
plotted for cell populations of 7.5 and 12.5 billion cells respectively with an additional line describing "eq.  
 
4.3.5 Zonation profiles for varying maximum oxygen uptake rate  
 
Various values of maximum oxygen uptake rate Vmax have been reported for hepatocytes so 
the significance of this parameter was examined in Figure 4.9.  A valid Operating Region 
could not be produced for a Vmax value of 11.25 µM/s for the standard plasma flow rate 
value in Table 2.1 (250 ml/min), so a Q value of 300 ml/min was considered instead.  
When using the lowest Vmax value of 2.93 µM/s, the entire BAL consists of periportal 
hepatocytes when operating on the "min limit. When Vmax is equal to 11.25 µM/s the 
perivenous zone is the largest in the BAL, occupying 47.9 – 49.9% of the cell volume 
depending on the fibre number (Fig. 4.9A). For this reason it was impossible to produce an 
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equal zone distribution for the upper limit Vmax value with a Qeq value of less than 300 
ml/min.  A lower Vmax value allows equal zone distribution to be achieved with a lower 
plasma flow rate.  In the case of Vmax equal to 2.93 µM/s, a minimum flow of 87 ml/min 
could produce periportal and pericentral zones each occupying 34.2% of the cell volume.  
Operating Region charts were constructed for each of the extreme Vmax values, though it 
was necessary to use a flow rate of 300 ml/min in order to produce a valid Operating 
Region for the higher oxygen uptake rate.  For the smaller maximal uptake rate of 2.93 
µM/s (Fig. 4.9C) there is a large Operating Region where the "eq line lies in the upper part 
of the region. In contrast, for a higher uptake rate of 11.25 µM/s the Operating Region is 
vanishingly small (Fig. 4.9D) and it is impossible to achieve and equal distribution of 
zones within it. 
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Figure 4.9: Visualization of the impact of varying oxygen uptake rates on zonation. (A) Distribution of 
metabolic zones in the case of (I) Vmax = 2.93 µM/s, (II) Vmax = 5.87 µM/s and (III) Vmax = 11.25 µM/s. (B) 
For a Vmax value of 11.25 µM/s, it was not possible to create an equal zone distribution for a Q value of less 
than 300 ml/min and hence that line is not included on the Qeq chart. (C and D) The Operating Regions are 
plotted for Vmax values of 2.93 and 11.25 µM/s respectively. It was necessary to use a plasma flow rate of 300 
ml/min in each of these charts in order to produce a valid Operating Region for the higher oxygen uptake 
rate.   
 
4.3.6 Influence of single or double cell layer on zonation profile 
 
Hepatocytes can be cultured as either a single or double layer on each hollow fibre, and the 
effect on the zone distribution can be seen in Figure 4.10A. The addition of an extra cell 
layer per fibre causes a gradual reduction in the size of the periportal and pericentral zones, 
accompanied by a corresponding increase in the perivenous zone size.  The periportal zone 
fractional size at the "max limit reduces from 26.8% for a cell monolayer to 22.1% for a 
double layer, or from 44.9% to 33.1% at the "min limit.  Conversely, the perivenous zone 
size increases from 46.0% to 51.2% of the cell volume at the "max limit or from 9.7% to 
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23.1% at the "min limit.  For a monolayer system, operating at Qeq (Fig. 4.10B) will 
produce periportal and perivenous zones of 33.2% fractional volume whereas they will 
each occupy 30.1% in the double layer system. 
 
 
 
Figure 4.10:  Impact of single or double layers of cells on zonation profiles. (A) Distribution of metabolic 
zones in the case of (I) a single cell layer and (II) a double cell layer model. (B) The Qeq plot for each case is 
also shown. (C) An Operating Region for the case of a double cell layer is shown. The "eq line lies outside of 
the region indicating it is impossible to obtain equal periportal and perivenous zones 
 
4.4 Discussion  
 
As in Chapter 3, a mathematical model of oxygen transport within a bioartificial liver was 
set up and solved using finite element software. The procedure was enhanced through the 
use of axial scaling of the modelling equations and the use of MATLAB script.  Once 
again, the results of the simulations were used to define Operating Regions within which 
the BAL could adequately oxygenate a defined cell population.  It was explained how 
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oxygen tensions within the bioreactor delineate three metabolic zones as seen in the liver in 
vivo.  This chapter describes how altering the design parameters of the BAL affect the 
distribution of these zones while remaining in the Operating Region. 
 
The effects of hollow fibre radius and length were illustrated in Figures 4.4 and 4.5.  It can 
be seen that lumen radius has very little effect on zonal distribution while fibre length has 
no influence.  These parameters are important, however, in forming the Operating Regions 
and hence determining the values of "min and "max. In Chapter 3 it was concluded that it 
was preferable to use numerous, shorter and thinner hollow fibres as opposed to fewer 
larger and longer fibres as this tended to produce wider Operating Regions and hence offer 
greater design flexibility and margin for error in the model.  Over the ranges considered, it 
appears that fibre length or radius do not affect the ability to equally distribute the 
periportal and perivenous zones.  Values of Qeq can be found within an acceptable range (< 
300 ml/min) and the fibre number "eq occupies roughly the centre of the Operating Region.  
As such fibre geometry is not a key factor in the distribution of the metabolic zones. 
 
A key parameter in the design of a BAL is the flow rate of plasma from the patient to the 
device.   As expected, increasing the flow rate of oxygen-carrying plasma into the BAL 
will increase the proportion of periportal hepatocytes.  However, a risk arises as a result of 
using high flow rates; the perivenous zone can become very small or disappear entirely.  
Hepatocytes in the perivenous zone play roles in the liver glucostat function and xenobiotic 
metabolism through expression of the relevant proteins.  If the BAL is over-oxygenated, 
these functions could be impaired or entirely absent from the system.  This situation 
highlights the need to mimic the in vivo oxygen gradient as closely as practically possible. 
The Operating Region charts clearly show that increased flow rates results in larger regions 
and hence offer more design flexibility. Also it can be seen that the position of the "eq line 
changes in each case as does its relative position with respect to the operating constraint 
lines.  It can be concluded that plasma flow rate is an important consideration with regards 
to desired zone distribution. 
 
The inlet oxygen tension to the BAL was previously chosen to be 90 mmHg as this is 
approximately equal to arterial oxygen levels and as seen in Chapter 3 was able to 
adequately oxygenate the BAL in most cases.  In vivo however the liver has a dual blood 
supply from the hepatic portal vein and hepatic artery.  Around two-thirds of the blood 
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supply is venous and hence hepatocytes actually experience oxygen tensions between 60-
65 mmHg, some way below 90 mmHg (Jungermann and Kietzmann, 2000).  The presence 
of haemoglobin as an oxygen-carrier ensures the lower inlet oxygen tension does not lead 
to cell necrosis due to anoxia.   As haemoglobin is assumed to have been separated from 
the blood plasma in the model presented here, it is necessary to operate with higher-than-
physiological oxygen tensions.  The periportal zone is restricted to a small volume in the 
case of 70 mmHg inlet oxygen tension whereas it dominates the cell volume when the 
plasma is oxygenated to 110 mmHg.   It can be concluded that 70 mmHg is too low to 
operate the BAL and hope to achieve equal zone distributions as flow rates above the 
technical limit of 300 ml/min would be required.  On the other hand, maximizing the 
oxygen content of the plasma appears to offer more flexibility in controlling the size of the 
metabolic zones.  A minimum flow rate of 122 ml/min is required to balance the zones in 
the case of inlet oxygen tension being 110 mmHg if the BAL is operated with the 
parameters of Table 2.1.  The duty of the plasma pump in the BAL can be reduced through 
use of higher oxygen tensions, though whether the hepatocytes will function to the same 
degree at non-physiological oxygen tensions is another question.  There is some evidence 
suggesting that hyperoxic environments can damage hepatocytes (Miyazaki et al., 1991). 
The Operating Region charts indicate that for the conditions considered, it is not possible 
to equally distribute the zones and remain within the Operating Region for each of the inlet 
oxygen tensions considered (70 and 110 mmHg).  Under a moderate oxygen tension 
however, this is possible as seen for example in Figure 4.4C where the same conditions are 
used but the inlet oxygen tension is 90 mmHg.  
 
The number of cells required in the BAL is subject to debate, with the patient’s residual 
liver function being a factor.  Generally it is regarded that the minimum number of 
hepatocytes should be 10% of the cell mass in the liver, corresponding to approximately 10 
billion cells (Allen et al., 2001, Sullivan et al., 2007, Morsiani et al., 2002).  A range of cell 
numbers around this figure was examined to see how this parameter affected the zone 
distribution.   Operating with a smaller number of cells corresponds to a lower required 
fibre number "min and hence the Operating Region widened.  This results in a greater 
degree of choice in regards to zonal distribution.  For the higher cell number of 12.5 billion 
the Operating Region is significantly constricted. As a result less control exists over the 
distribution of the metabolic zones though according to the chart for Qeq a plasma flow rate 
from 230 – 300 ml/min will cause each of the metabolic zones to occupy approximately 
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one-third of the cell volume, depending on the fibre number. The Operating Region charts 
also indicate that equal zone distributions can be found within them.  This would indicate 
that a greater number of cells could reside in the BAL while still maintaining equal zone 
distribution.  According to our calculations (not presented), up to 16.2 billion cells could 
be supported in the device while maintaining equal zone distribution with a maximum 
plasma flow rate Q of 300 ml/min.  The parameters of Table 4.1 were used to calculate this 
value. 
 
In modelling oxygen uptake by hepatocytes, one parameter that is difficult to accurately 
identify is the maximum rate of oxygen uptake Vmax.  The parameter is very sensitive to 
culture conditions and a range of values have been reported in the literature, from 24 to 
900 amol/cell/s (Patzer, 2004).    For the upper limit value studied here (11.25 µM/s) it was 
found that viable Operating Regions could only be defined when the maximum flow rate of 
300 ml/min was used.   For a low Vmax (2.93 µM/s) it is possible that the entire BAL can be 
occupied by periportal hepatocytes, an undesirable situation which would unbalance the 
functions of the BAL.  However, a lot of control does exist over the zone distribution due 
to the wide Operating Region and a lower inlet flow rate or oxygen tension could 
compensate for the lower oxygen demand.  On the other hand, if the hepatocytes have a 
high oxygen demand there is almost no control over the zone distribution.  It would be 
necessary to increase the plasma oxygen content or reduce the number of cells inoculated 
in the BAL in order to more evenly distribute the zones. Under the standard conditions of 
Table 2.1 and an increased flow rate of 300 ml/min, it is impossible to achieve equal zone 
distribution within the Operating Region for the upper value of Vmax. In a real system it is 
likely that the oxygen demand will vary transiently, beginning high and then decreasing as 
the cells adapt to their new environment (Patzer, 2004).  
 
The mathematical model from the previous chapter was modified to account for cells being 
arranged as a double layer on each fibre as opposed to solely being monolayers.  By 
increasing the number of cells surrounding each fibre, fewer fibres are required in the BAL 
which is beneficial from a manufacturing point of view.  However, it can be seen in the 
results above that a double hepatocyte layer around each hollow fibre causes the relative 
size of the perivenous zone to increase over the monolayer model. The periportal zone 
shrinks while the pericentral zone remains relatively unchanged in size.   As a result, the 
minimum flow rate required to achieve equal zone distribution is greater in the double 
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layer system, 227 ml/min opposed to 185 ml/min in the monolayer model.  With a flow 
rate of 250 ml/min as in the standard parameters of Table 4.1, it is impossible to achieve 
equal zone distribution within the Operating Region when considering a double cell layer 
system.  
 
It has been assumed that an equal distribution of the periportal, pericentral and perivenous 
zones would be optimal with respect to BAL functionality. For this reason, charts were 
produced that give values of plasma flow rate and fibre number that will cause the 
periportal and perivenous zones to occupy the same proportion of the cell volume.  
However, perhaps the relative importance of each of the liver functions should be 
established before making this conclusion.  For example, ammonia clearance takes place 
primarily in periportal hepatocytes whereas xenobiotic metabolism is typically seen in the 
perivenous zone.  If ammonia clearance could be achieved through artificial means such as 
adsorption or filtration in series with the BAL as seen in several hybrid devices such as the 
HepaMate or TECA-HALSS (Xue et al., 2001, Gerlach et al., 1994, Rozga et al., 1992), 
then perhaps it would be beneficial to increase the proportion of perivenous hepatocytes 
that detoxify drug molecules.  Further experimental and anecdotal evidence is required to 
establish this hypothesis.   
 
4.5 Conclusions 
 
Oxygen is a primary regulator of liver cell heterogeneity and hence is key in the 
coordination of various liver functions.  In order to design a BAL that can function in a 
similar manner to the in vivo organ, physiological gradients of oxygen tension should be 
replicated as closely as possible within the extracorporeal device.   Using a mathematical 
model and operating parameters that satisfy both oxygenation and cell number constraints, 
it was possible to see how each parameter was significant in controlling the distribution of 
the metabolic zones.  As expected, increasing oxygenation of the BAL through higher flow 
rates and inlet oxygen tensions allows a greater range of zone sizes. However, it is possible 
to over-oxygenate the hepatocytes in a way that the perivenous zone is either small or 
absent entirely, potentially impairing the functionality of the BAL.  Conversely, when 
using higher cell loadings or cells with higher oxygen demands the periportal zone can be 
reduced in size.  This study shows how it is possible to control the distribution of the liver 
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metabolic zones, while remaining within the operating limits of the BAL design.  By 
making these considerations, the efficacy of BAL designs should improve and take a 
further step towards clinical use.  
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Chapter 5: Modelling and Optimization of Commerical 
Bioartificial Liver Systems 
 
5.1 Introduction 
 
In the previous chapters, a mathematical modelling approach to studying oxygen mass 
transport and its ramifications in BALs has been developed.  The results allowed 
comparisons to be made between various BAL designs in terms of their likely viability or 
effectiveness in terms of replicating the three metabolic zones present in the liver.  In this 
chapter, the concepts outlined previously are expanded and applied specifically to existing 
commercial BAL designs: the HepaMate, Bioartificial Liver Support System (BLSS) and 
Extracorporeal Liver Assist Device (ELAD).  These devices represent the BALs that have 
undergone the most extensive clinical trials and are closest to clinical application. 
 
5.1.1 Bioartificial liver background 
 
HepaMate  
 
Currently owned by HepaLife Biosystems, Inc., the HepaMate (Fig. 5.1) was previously 
known as the HepatAssist.  This BAL was first developed by a group at the Cedars-Sinai 
Medical Centre in Los Angeles, California (Rozga et al., 1992) and was involved in the 
largest single clinical trial of all BALs to date.  This model housed approximately 5 billion 
cryopreserved porcine hepatocytes co-cultured with cellulose microcarriers.  Its safety was 
demonstrated in a Phase I multicentre trial where 32 of 39 acute liver failure patients were 
bridged to transplantation, with 6 recovering spontaneously (Mullon and Pitkin, 1999).  A 
Phase II/III clinical trial was then initiated where 171 patients with acute liver failure or 
nonfunction after transplant were enrolled, with 86 receiving treatment from a BAL and 
the rest forming a control group (Demetriou et al., 2003).    It was found that the BAL 
group had an increased survival rate, but only in a patient subgroup and the treatment has 
not yet obtained FDA approval (Pryor and Vacanti, 2008).  Currently there is no 
information to suggest clinical trials are ongoing. 
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Figure 5.1: A schematic of the HepaMate BAL, from HepaLife™ website (2011) 
 
Extracorporeal Liver Assist Device (ELAD) 
 
Originally developed by a group at the Baylor College of Medicine in Houston, Texas, 
(Sussman et al., 1991) the ELAD is now being developed and marketed by Vital 
Therapies, Inc. of San Diego, California. The design of the bioreactor has changed 
significantly (Fig. 2.7), originally consisting of a single hollow fibre cartridge perfused by 
whole blood to now perfusing separated plasma through four parallel hollow fibre 
bioreactors (Brotherton et al., 2007).  A contentious issue surrounding the ELAD is the use 
of an immortalized human cell line, C3A cells.  The use of tumour-derived cells raises 
some questions of safety (Rozga et al., 1992).  There is also a suggestion that C3A cells do 
not perform certain liver functions as well as primary hepatocytes (Nyberg et al., 1994).  
The design does incorporate a cell filter after the bioreactor stage in order to prevent 
foreign cells reaching the patient and to date there have been no reported issues related to 
the cell type in patients treated with the ELAD.  The ELAD has completed 6 clinical trials 
to date, including a randomized controlled study at King’s College Hospital, London (Ellis 
et al., 1996).  An abnormally high survival rate in the control patient group (75% when 
50% was expected) confounded any observable benefit of ELAD treatment in terms of 
survival rates.  More recently a Phase II multicentre trial in China consisting of 17 patients 
was carried out where 90 day survival rates appeared to improve over controls (39% versus 
25%) and the device was well tolerated (Hillebrand et al., 2010).  According to the 
company’s website, clinical trials are ongoing in several countries and producing positive 
results.  
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Bioartificial Liver Support System (BLSS) 
 
The BLSS is owned by Excorp Medical, Inc. a company based in Minnesota, USA with 
operations also in China.  Unique to this BAL compared to the previous two is the use of 
whole blood rather than separated plasma in the hollow fibre bioreactor stage of the BAL 
(Fig. 5.2). Patzer et al have suggested this improves mass transfer over using fractionated 
plasma (Patzer et al., 2002a).  Like the HepaMate, porcine hepatocytes are used, and the 
system was used to test whether the transfer of porcine endogenous retrovirus (PERV) was 
an issue (Kuddus et al., 2002).  The results suggested that PERV transmission did not 
occur under standard conditions and that the BLSS was safe.  Pre-clinical studies have 
been completed (Patzer et al., 2002b, Patzer et al., 1999) but there has been limited 
experience with the BLSS in human patients with a study of one individual (Mazariegos et 
al., 2002) and a Phase I trial involving four patients (Mazariegos et al., 2001).  Phase I/II 
clinical trials in the USA and China are currently being planned according to the company 
website. 
 
The BALs described above are in various stages of development and clinical trials.  By 
using available literature data on each of the designs, they can be incorporated into updated 
versions of the mathematical models described in the previous chapters.  The resulting 
oxygen tension and zonation profiles can then be assessed and in turn improved by 
modifying each of the designs in some way.  This is achieved by defining two optimization 
protocols that are incorporated into the mathematical model to return optimal 
configurations for each of the BALs.   
 
 
Figure 5.2:  A schematic of the BLSS, from the Excorp Medical, Inc. website (2011) 
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5.2 Theoretical Aspects 
 
5.2.1 Mass transport equations 
 
The system of modelling equations employed in this study is based on that described in 
previous chapters, with some modifications to describe the unique features of each BAL.  
Also, the definition of the metabolic zones is updated to allow better comparison with in 
vivo oxygen tension gradients.  In each case the convection-diffusion equation (Eq. 3.1) is 
solved to obtain the oxygen tension profiles, where D is the diffusion coefficient, c is the 
species concentration and V is the reaction term: 
VccD −∇=∇−∇ .)( u  (3.1) 
As in Chapters 3 and 4 the Krogh cylinder model is used to describe each BAL where the 
form of the convection-diffusion differs between the lumen, membrane and ECS 
subdomains.  The system of equations employed for each BAL is outlined below. 
 
HepaMate and ELAD model equations 
 
The HepaMate and ELAD designs are very similar to the BAL models solved in previous 
chapters, with one significant difference – the cells do not form a layer on the membrane in 
the ECS but instead are suspended in a gel matrix. The only practical difference this makes 
to Equation 3.4 is an additional cell volume fraction, ε, which is added to the transport 
equation in the ECS (Eq. 5.1).  All other equations and boundary conditions stated in 
Chapter 3 are unchanged. 
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BLSS model equations 
 
The BLSS is distinct from the other two BAL designs in two important ways.  First of all, 
whole blood is used to perfuse the bioreactor rather than fractionated plasma.  This is 
important as the presence of haemoglobin in the red blood cells significantly affects 
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oxygen transport and must be accounted for in the model equations.  The association of 
oxygen and haemoglobin in the blood stream necessitates an extra equation system in the 
fibre lumen.  The reaction term VHb is added to the oxygen transport equation in the lumen 
to represent the rate of dissociation of oxygen from haemoglobin (Eq. 5.2). Here, blood is 
assumed to be a Newtonian fluid. This is not true in practice as blood exhibits shear-
thinning behaviour and hence the velocity profile will not be a typical Poseuille flow. In 
addition, the added blood components may affect oxygen diffusivity. Here the flow and 
diffusion coefficient are assumed to be equal to those in plasma, in order to simplify the 
model.  
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In order to define the rate of oxygen dissociation, an approach developed by Moll (1968) 
and subsequently used by Sullivan et al (2007, 2008) is employed.  Here the 
binding/release of oxygen from haemoglobin is considered a single-step reversible 
reaction.  VHb can be considered to be the rate of the binding minus the rate of release of 
oxygen to produce Equation 5.3, where kO2 is the rate constant for oxygen release, Hb is 
the concentration of haemoglobin in the blood and S is the fractional saturation of 
haemoglobin.  
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Seq in the above equation is the haemoglobin saturation when blood is in equilibrium with 
the gas phase and is a function of local oxygen tension.  In this case the Margaria equation 
is chosen to describe the relationship (Margaria, 1963).    This equation is a simplification 
of the earlier Adair equation and is based on the observation that the affinity for the fourth 
and final oxygenation of the haemoglobin molecule is 125 times greater than the previous 
three steps.  The form of the Margaria equation is given below (Eq. 5.5). Here K and m are 
constants calculated from curve-fitting experimental oxygen dissociation curves. 
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In order to calculate the oxygen tension profile in the lumen, a second convection-diffusion 
equation representing the haemoglobin-bound oxygen must be solved simultaneously (Eq. 
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5.5).  In this equation the reaction term VHb is present but opposite in sign relative to the 
transport equation for unbound oxygen (Eq. 5.2).   The diffusion coefficient for 
haemoglobin in the blood is represented by DHb.   
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This equation for haemoglobin saturation S also has its own associated boundary 
conditions.  At the inlet, the blood is considered to be in equilibrium with the gas phase 
(Eq. 5.6).  Red blood cells do not pass through the fibre membrane and so there are no flux 
boundary conditions at both the lumen centre-line (due to symmetry) and membrane 
surface (Eq. 5.7). A zero diffusive flux boundary condition is assumed at the lumen outlet 
(Eq. 5.8). 
eqSrS =),( 0  (5.6) 
00 =
∂
∂
=
∂
∂
),(),( zRS
r
zS
r
l  (5.7) 
0=
∂
∂
),( LrS
z
 (5.8) 
In addition to whole blood being used, the ECS ports of the BLSS bioreactor are opened 
and cell medium is circulated to remove any substances harmful to the cells (Patzer et al., 
2002b).  However, the ECS flow rate is only 0.25% of that compared to the flow through 
the fibres however and was found to be negligible in terms of affecting oxygen profiles in 
the BLSS Krogh cylinder model (data not shown). However, the open ECS port acts as 
another source of oxygen for the cells and the boundary conditions must reflect this.  It is 
unclear what this secondary inlet oxygen tension is so in this model it is assumed to be 
equal to the lumen inlet oxygen tension (Eq. 5.9). 
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Similar to the HepaMate and ELAD, the porcine hepatocytes used in the BLSS are 
suspended in a collagen gel in the ECS and don’t form layers on the fibre. Hence Equation 
5.1 also applies to the ECS oxygen transport equation in the BLSS model.  
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5.2.2 Metabolic zone definitions 
 
As in the Chapter 4, the size of each metabolic zone can be estimated from the modelling 
results. In this work, the definitions are updated in order to improve comparisons between 
the BALs and the in vivo oxygen tension profiles.  In the previous chapter, all hepatocytes 
experiencing oxygen tensions above 60 mmHg were defined as being periportal.  In vivo 
however, the maximum oxygen tension in the liver sinusoids is approximately 70 mmHg 
(Allen and Bhatia, 2003). Hence all cells experiencing higher oxygen tensions are now 
assigned to a ‘hyperoxic’ zone to reflect the non-physiological conditions.  It is unclear 
what effect if any the higher oxygen tensions will have on cell function compared to 
normal periportal hepatocytes, but it is useful when comparing the zonation distribution 
profiles the in vivo oxygen spectrum.  By the same logic, hepatocytes that experience 
oxygen tensions lower than 25 mmHg are no longer considered to be within the perivenous 
zone but in a new ‘hypoxic’ zone.  An ‘anoxic’ zone is defined for hepatocytes where the 
local oxygen tension is less than 10 mmHg as these cells are vulnerable to necrosis 
(Consolo et al., 2009).  In previous chapters a value of 2 mmHg was to describe the anoxic 
limit (De Groot et al., 1988), the new higher value represents a higher safety factor in BAL 
designs. Table 5.1 summarizes how each zone is defined. 
 
Table 5.1: The range of oxygen tensions that defines each of the metabolic zones 
Zone Oxygen Tension Range (mmHg) 
Hyperoxic > 70 
Periportal 60 – 70 
Pericentral 35 – 60 
Perivenous 25 – 35 
Hypoxic 10 – 25 
Anoxic < 10 
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5.2.3 BAL optimization protocols 
 
Once zonation profiles have been established for the BALs under their standard operating 
conditions as defined in literature, the main objective in this chapter is to ascertain whether 
operating conditions could be changed to create more evenly distributed profiles.  The 
approach taken here is to identify what plasma/blood rate will result in the ideal zonation 
profile. However, there is a question over how to define an ‘evenly distributed profile’.  In 
this work, two optimization protocols are followed.  The first, Optimization Protocol I, 
seeks to equalize the combined size of the hyperoxic and periportal zones and the 
combined size of the perivenous and hypoxic zones i.e. Optimization Protocol I returns a 
flow rate that minimizes the difference in the size of the high and low oxygen tension 
zones.  The second protocol, Optimization Protocol II, seeks to equalize the size of the 
periportal and perivenous zones specifically.  This protocol does not consider hepatocytes 
outside of the physiological range of oxygen tension as their functionality is unknown.  For 
both protocols, there is also a condition that no cells in the BAL are exposed to an anoxic 
environment. Figure 5.3 illustrates how the Optimization Protocols are defined.  
 
Figure 5.3: The zone distribution charts for each Optimization Protocol.  The = sign shows the relevant 
metabolic zones for each case. Protocol I seeks to match the combined high oxygen zone size with the low 
oxygen zone size. Protocol II only considers the size of the periportal and perivenous zones. 
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5.2.4 Modelling parameter values 
 
To model each of the BALs described above parameter values must be found which 
describe the uniqueness of each system.  A literature search was performed to identify as 
many as possible of the parameter values needed to accurately simulate each BAL. Table 
5.2 details the modelling parameters that were common to each BAL model whereas Table 
5.3 outlines the values unique to each BAL. In some cases it was necessary to estimate 
likely values as some information has not been reported elsewhere to the author’s 
knowledge.   
Table 5.2: A list of the common parameters in each BAL model 
 Parameter Value Reference 
Dplasma (m
2/s) 3 x 10-9 (Piret and Cooney, 1991) 
Dhep (m
2/s) 2.5 x 10-9 Calculated 
Km (mmHg) 3 (Sullivan et al., 2007) 
 
A number of the parameters listed in Tables 5.2 and 5.3 were not directly taken from 
literature sources but calculated or estimated. For example, literature values for the Krogh 
cylinder outer radius Re are difficult to find for the specific BALs being considered here.  
In order to estimate this parameter, the assumption was made that the cell volume fraction 
in the ECS of each bioreactor was 0.5.  This is based on the knowledge that an interstitial 
space volume fraction of 0.4 – 0.55 was reported for hepatomas (Gullino et al., 1965, 
Moussy, 2003). Assuming that HepG2/C3A cells and porcine hepatocytes have diameters 
of 16 µm (Hay et al., 2000) and 25 µm (Sullivan et al., 2007) respectively and knowing 
how many hollow fibres and total cell number are in each BAL, the value of Re can be 
calculated by Equation 5.10 where dcell represents the cell diameter. Table 5.3 contains the 
calculated values for Re for each BAL. 
L
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(5.10) 
A fibre number " of 870 was assigned to the HepaMate model in Table 5.3. This figure 
was calculated on the basis of previous literature values.  Hay et al. (2001) reported " to be 
670 and Re to be 576 µm but at that time the HepaMate (in it’s previous incarnation, the 
Chapter 5: Modelling and Optimization of Commercial Bioartificial Liver Systems 
 104 
HepatAssist) housed only 5 billion cells. Today the HepaMate is known to contain 14 
billion cells.  An increase of fibre number " to 870, assuming an unchanged cell density in 
the ECS, reflects the increased cell number while maintaining the previous value of Re. 
 
The maximal oxygen uptake rate Vmax values were also indirectly obtained from literature.  
These values were calculated through data supplied by Nyberg et al (1994) for rat 
hepatocytes and HepG2 cells in a 3D gel entrapment bioreactor.  In this study the oxygen 
consumption rates were measured on a per cell basis i.e. mol/cell/s. In order to convert 
them to volumetric oxygen uptake rates, the values are divided by the volume of an 
individual cell assuming they are spherical with diameters as reported above.  As a result a 
value of 5.87 x 10-3 mol/m3/s was assigned to the HepaMate and BLSS models which both 
use primary porcine hepatocytes.  Though the animal is different this value was chosen to 
be representative of mammalian primary hepatocytes.  The Vmax value for the ELAD model 
was calculated to be 11.2 x 10-3 mol/m3/s.   
 
Oxygen diffusion rates through the membrane were calculated using an equation derived 
by Renkin (1954) to describe restricted diffusion through membrane pores. Using the 
Einstein-Stokes equation to estimate the radius of an oxygen molecule, it was found by the 
Renkin equation that for typical membrane pore sizes oxygen diffusion was not 
significantly restricted.  As a result the same diffusion coefficient Dplasma for oxygen is 
applied to both the lumen and membrane subdomains in the Krogh cylinder model.  The 
oxygen diffusion coefficient in the ECS Dhep was calculated as the mean of Dplasma and the 
diffusion coefficient of oxygen in tissue which has been given as 2 x 10-9 m2/s (Piret and 
Cooney, 1991).  This assumes the cells volume fraction ε was 0.5 as stated above.   
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Extra parameters are also needed to describe the oxygen and haemoglobin binding/release 
kinetics in the BLSS model. The values used are shown below in Table 5.4. 
 
Table 5.4: The values for the parameters required to model whole blood in the BLSS model 
 Value Reference 
Hb 8.8 mol/m3 (Chen and Palmer, 2009) 
DHb 6.8 x 10
-15 m2/s (Sullivan et al., 2007) 
kO2 33.5 s
-1 (Chen and Palmer, 2009) 
K 0.01278 mmHg-1 (Hay et al., 2000) 
m 125 (Margaria, 1963) 
 
5.2.5 Modelling strategy 
 
As in previous chapters the finite element multiphysics software package COMSOL 3.5a is 
used to solve the modelling equations.  The Krogh cylinder is constructed and the 
subdomain and boundary condition equations are input. As in the previous chapter, as the 
Krogh cylinder models are of a very high aspect ratio the geometry is scaled in both axial 
and radial directions. This avoids problems in the COMSOL solver algorithms and allows 
high-quality finite-elements. As a result all of the model equations must be scaled 
appropriately to reflect the new coordinate system.  MATLAB scripting is used to build 
each model rather than the COMSOL GUI as this allows more efficient optimization of the 
plasma/blood flow rates.  Essentially, the MATLAB script allows each BAL model to be 
solved for a range of flow rates and assess the zonation pattern produced for each one. The 
value of Q to the nearest 5 ml/min is returned when the ideal zonation pattern is found for 
each of the optimization protocols. While it is possible to be more specific with regards to 
the optimized flow rates, the assumptions made in the model mean that the increased 
accuracy would not justify the extra computational effort required. 
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5.3 Results 
 
5.3.1 HepaMate standard and optimized models 
 
Standard HepaMate model 
 
Figure 5.4 is a representation of the oxygen profile in a Krogh cylinder sub-unit 
representing the HepaMate design under standard operating conditions. Reynolds and 
Peclet numbers can be calculated as described in Section 3.3.1. Under the standard 
operating conditions of the HepaMate as seen in Table 5.3, Reynolds number varies 
between 7.6 and 15.2 and hence the flow is laminar. Peclet number will vary between 0.9 
and 1.8 indicating neither convection nor diffusion dominates in the fibre lumen. A 
parameter to describe the balance of oxygen diffusion and consumption in the cell region, 
as described in Section 3.3.1 and in work by Shipley et al. (2010), is of order 1. From this 
it can be concluded diffusion and reaction mechanisms will both be significant in the cell 
region.  Figure 5.5 displays the corresponding metabolic zone distribution profile.  As the 
standard plasma flow rate is not known for the HepaMate, a range of values was examined 
in this figure.  For flow rates of 200 and 300 ml/min, which are typical of this application, 
there are significant regions of anoxia and hence probable cell necrosis.  For a flow rate of 
400 ml/min, the zone distribution is skewed towards the low oxygen zones over the higher 
oxygen environment zones.  The periportal zone only occupies 2.5% in this instance.  
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Figure 5.4: The oxygen profile for the HepaMate model under standard conditions.  The minimum 
oxygen partial pressure is 12.1 mmHg when operating with a plasma flow rate of 400 ml/min. A 
dimensionless coordinate system is used. 
 
Figure 5.5:  The standard zonation profile in the HepaMate under standard conditions. As the flow rate 
is not known, three representative values are studied; 200, 300 and 400 ml/min.   
 
Optimized HepaMate Modelling 
 
In Figure 5.6A, the existing HepaMate model is optimized with respect to plasma flow 
rate. For the first optimization protocol, which seeks to equalize the high and low oxygen 
environment zones, a flow rate of 400 ml/min (the maximum considered allowable) 
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produced a profile where the periportal zone only occupied 2.5% of the cell volume 
whereas the perivenous and hypoxic regions jointly occupied 59.6% of the cell volume.  A 
similar picture emerges for Optimization Protocol II where a flow rate of 375 ml/min 
produced the distribution.  The periportal zone makes up 2.2% of the cell volume while the 
perivenous zone occupies 22.2%.  Clearly the optimization protocol has failed to produce 
well-balanced zones in this case.     
 
For Figure 5.6B, the design of the hollow fibre module was changed. This was done to 
produce more evenly distributed zone profiles.  The reasons for this are explained further 
in the discussion. Table 5.5 shows the original and modified hollow fibre parameters.   For 
optimization protocol I, a flow rate of 315 ml/min caused the high oxygen zones (i.e. the 
hyperoxic and periportal zones) to occupy 28.3% of the cell volume and the low oxygen 
zones to occupy 27.8%.  For Optimization Protocol II, a flow rate of 355 ml/min induced 
the periportal zone and perivenous zones to occupy 19.1% and 18.4% of the cell volumes 
respectively.  
 
 
 
Figure 5.6: Optimized zonation profiles for the HepaMate. (A) The flow rate of the HepaMate is 
optimized for two situations. Q = 400 ml/min for the first optimization protocol and Q = 375 ml/min for the 
second optimization protocol. (B) The HepaMate hollow fibre design is changed (Table 5.5) and the optimal 
flow rates are recalculated.  Q = 315 ml/min for the first protocol and Q = 355 ml/min for the second 
optimization protocol. 
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Table 5.5: The old and new hollow fibre parameters for the optimization of the HepaMate 
 
Old Parameters 
New parameters 
for optimization 
Lumen radius Rl (µm) 320 160 
Outer fibre radius Rm (µm) 380 190 
Fibre length L (cm) 45 25 
Fibre number N  870 4800 
Krogh cylinder radius Re (µm) 576 576 
 
5.3.2 BLSS standard and optimized models 
 
Standard BLSS model  
 
Figure 5.7 shows the oxygen profile for the BLSS under standard operating conditions with 
a normal human hematocrit when modelled using COMSOL and the relevant equations 
above.  The minimum oxygen partial pressure in the Krogh cylinder is 77.1 mmHg.  The 
corresponding zonation profile can be seen in Figure 5.8, where two inlet oxygen tensions 
were considered.  In the former case, all hepatocytes are within a hyperoxic environment 
whereas in the latter the majority (82.8%) are within the periportal zone.  Reynolds number 
for the standard flow conditions in the BLSS takes a value of approximately 1.5-2 and 
Peclet number is approximately 0.1. This indicates blood flow is laminar and diffusive 
transport in the lumen is significant. The dimensionless parameter characterizing 
diffusion/reaction balance in the cell region varies between approximately 0.1 – 1, showing 
both mechanisms are significant.  
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Figure 5.7:  The oxygen profile in the standard model of the BLSS, with a full haematocrit and a blood 
flow rate of 200 ml/min.  The minimum oxygen tension in the model is 75.3 mmHg.  
 
Figure 5.8:  The zone distribution in the BLSS under the standard operating parameters and a blood 
flow rate of 200 ml/min. Each bar represents a different inlet partial pressure of oxygen.  
 
Optimized BLSS model 
 
Initially the optimal flow rates were found based on the standard BLSS design, i.e. using 
whole blood.  The optimized zone distribution can be seen in Figure 5.9A.  An inlet partial 
pressure of 70 mmHg was used in order to mimic in vivo oxygen conditions.  However, the 
optimization protocols fail in this instance as the periportal and perivenous zone occupy 
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8.2% and 5.2% of the cell volume respectively with the remainder residing in the 
pericentral zone. The pericentral zone is dominant and the zonation profile is unbalanced. 
This occurs at a blood flow rate of 15 ml/min for both optimization protocols. 
 
In Figure 5.9B, the red blood cells are removed from the model and the inlet oxygen 
concentration raised to 90 mmHg. This was done to widen and reposition the oxygen 
tension spectrum in the BAL. For optimization protocol I the high oxygen zones make up 
35.6% of the cell volume, while the low oxygen zones occupy 28.4%. This occurs when a 
plasma flow rate of 200 ml/min. The periportal and perivenous zones occupy 16.3% and 
16.8% of the cell volume respectively for optimization protocol II, with a flow rate of 225 
ml/min. 
 
Figure 5.9: Optimized zone distributions for the BLSS. (A) The optimal zone distribution in the case of a 
full hematocrit and an inlet oxygen tension of 70 mmHg.  The optimal flow rate is 15 ml/min for both 
optimization protocols is the same and hence only one bar is present. (B)  By removing the red blood cells 
and increasing the inlet oxygen tension to 90 mmHg, the above optimal zone patterns are achieved. The flow 
rate for protocol I is 200 ml/min and for protocol II it is 225 ml/min. 
5.3.3 ELAD standard and optimized models 
 
Standard ELAD Model 
 
Using the available literature values for the ELAD design parameters, an oxygen tension 
profile in the corresponding Krogh cylinder sub-unit can be produced as seen below in 
Figure 5.10.  The zonation profile for the standard ELAD set-up is in Figure 5.11, where 
two inlet partial pressures are tested.  In either case the range of oxygen tension is too high 
for low oxygen zones to appear, especially with a 90 mmHg inlet oxygen tension where the 
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whole cell volume falls into the hyperoxic zone. Reynolds number under standard 
operating conditions is approximately 6.6 and Peclet number is calculated as 0.5. These 
conditions are consistent with the other models studied so far, where flow is laminar and 
convection and diffusion are both significant. A value of 0.2 for the diffusion/reaction 
parameter in the cell region shows that diffusion is relatively more significant.  
 
Figure 5.10: The oxygen profile in the standard model of the ELAD.  The minimum oxygen tension in 
the model is 74.8 mmHg when inlet oxygen tension is set to 90 mmHg. 
 
Figure 5.11: The zonation profile in the ELAD under standard conditions, for two inlet oxygen partial 
pressures.  When the inlet oxygen partial pressure is 90 mmHg, all zones bar the hyperoxic zone are absent. 
For the lower inlet tension, the cells are approximately equally divided between the periportal and pericentral 
zones. 
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Optimized ELAD model 
 
Figure 5.12A shows the optimal zonation profile with an inlet oxygen tension of 70 
mmHg.  In this case both optimization protocols produce the same result; a profile where 
the periportal and perivenous zones occupy 18.3% and 17.0% of the cell volume 
respectively.  This occurs when a plasma flow rate Q of 185 ml/min is employed. For 
Figure 5.12B, the inlet oxygen tension is raised to 90 mmHg. When the plasma flow rate is 
optimized to 90 ml/min by protocol I, the high oxygen and low oxygen zones occupy 
35.4% and 31.3% of the cell volume respectively.  Optimization protocol II results in a 
flow rate of 105 ml/min and the periportal and perivenous zones occupy 14.4% and 15.1% 
of the cell volume respectively. 
 
Figure 5.12:  The optimized zone profiles for the ELAD with varying inlet oxygen tension.  (A) With an 
inlet tension of 70 mmHg the plasma flowrate for both optimization protocols is 185 ml/min.   (B) An inlet 
oxygen tension of 90 mmHg was employed.  The plasma flow rate for protocol I was 90 ml/min and for 
protocol II was 105 ml/min. 
 
5.4 Discussion 
 
In this chapter, the techniques and findings from previous chapters were applied to existing 
privately-owned BAL designs that are currently undergoing clinical trials. This involved 
looking at the existing BAL designs and operating parameters and then applying the 
mathematical model developed previously to them. The concepts of the Operating Region 
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and zonation analysis could then be utilized. As mentioned in the discussion of Chapter 4, 
liver zonation is a physiological feature that doesn’t appear to be fully considered in 
existing BAL designs.  This view is supported by the modelling results for each of the 
BALs operating under standard conditions where the zone distribution profiles appear to be 
skewed towards either high or low oxygen environments.  The plasma/blood flow rates 
were also optimized for each design to improve the distribution of the metabolic zones.  
Two different protocols for optimization were defined, the first matching the combined 
sizes of the high and low oxygen zones and the second that matches the size of the 
periportal and perivenous zones specifically. For the HepaMate and BLSS however it was 
found that a fundamental change to the BAL design, a change in fibre number and size for 
the former and the removal of red blood cells in the latter, was necessary in order for the 
optimization protocols to produce well balanced zone distributions. 
 
In the case of the HepaMate it was unclear from literature what plasma flow rate is used 
for clinical applications.  Hence in the standard parameter model a range of flow rates from 
200 – 400 ml/min was examined. This corresponded with the range of flow rates modelled 
by Hay et al (2001),  though their upper limit value of 600 ml/min was ignored as it is not 
clear whether this flow rate can be achieved in a clinical setting.  This is based on the 
assumption of previous chapters that the plasma flow rate was limited to approximately 
300 ml/min due to technical and rheological constraints (Pless and Sauer, 2005).   In any 
case, the modelling results revealed that oxygen deficiency could be problematic in the 
HepaMate as anoxic zones were present for flow rates up to 300 ml/min.  Even in the case 
of the maximum flow rate of 400 ml/min, the zone distribution was still skewed towards 
the low oxygen metabolic zones with the periportal hepatocytes occupying only a very 
small fraction of the cell volume.  In light of this, a means to more evenly distribute the 
metabolic zones should be found. 
 
For the first attempt at optimizing the plasma flow rate, it is clear that whatever flow rate is 
employed the periportal zone becomes exceedingly small.  Clearly some other aspect of the 
HepaMate design must be addressed before a substantial improvement can be made.  
Several options are available: increase the inlet oxygen tension to the device; reduce the 
number of hepatocytes within the ECS; increase the flow rate even further or somehow 
change the hollow fibre bundle design. It is undesirable to reduce the cell population 
within the BAL device as this may have implications for the BAL’s functionality.  Also, 
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increasing the inlet oxygen tension would further distance the cell environment from their 
in vivo state where the maximum oxygen tension is typically 70-90 mmHg. Increasing 
plasma flow rate is also technically difficult and ineffective as can be seen in the relatively 
unchanged size of the periportal zone for flow rates of 200-400 ml/min. A further option 
may be to use whole blood to increase oxygen delivery to the cell mass, though this may 
bring issues relating to blood clotting and fibre blocking and hence is not ideal.  All that 
remains is the latter option, to alter the hollow fibre design.   
 
In Chapter 3, it was concluded that short, small-bore and numerous fibres tended to 
produce wider Operating Regions.  Larger Operating Regions also allow a greater range of 
zone distribution as seen in Chapter 4.  In the HepaMate design, literature values indicate 
that the hollow fibres have a relatively large lumen radius of 320 µm and a length of 45 
cm.  In addition, there are only 870 fibres in the entire bundle when the fibre number is 
updated to take account of the increased cell population.  The resulting interfibre distance 
is approximately 392 µm.  This is a large distance for oxygen to diffuse through tissue, as 
in the body the maximum diffusion distance is approximately 200 µm (Palsson, 2004). By 
increasing the fibre number and making them shorter, it should allow greater control over 
the range of possible zone distributions.  As an example to illustrate this, new fibre design 
parameters were used for the optimization protocols (Table 5.5).  This allows for a much 
more even distribution of the zones with balance between the high and low oxygen 
metabolic zones. 
 
The modelling results for the BLSS operating under standard conditions revealed that in 
contrast to the HepaMate, oxygen supply was not limited.  However, the model suggests 
that the oxygen tensions in the BLSS occupy too high a range.  Two inlet oxygen tensions 
were considered, 90 mmHg as this figure was used in previous chapters and is 
approximately equivalent to arterial blood and 70 mmHg as this corresponds to 
physiological oxygen tension in the liver.  In both cases the perivenous zone is completely 
absent from the zonation profile and as a result it may be inferred that some liver functions 
in the BLSS may be compromised.  
 
In attempting to optimize the blood flow rate in the BLSS under standard conditions, it was 
found that a very low flow rate of 15 ml/min produced a pattern that still appeared very 
unbalanced with the pericentral zone occupying almost all of the cell volume.  It is clear 
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that while the presence of red blood cells and their haemoglobin ensures that the cells will 
not be starved of oxygen, the resulting spectrums of oxygen tension are not physiologically 
relevant.  It isn’t feasible to further reduce the blood flow rate as this will likely cause other 
nutrients e.g. glucose to become limiting. It was decided to model the BLSS in the absence 
of red blood cells, i.e. to remove the effect of haemoglobin on the oxygen transport 
equations.  The resulting optimized zone profiles are significantly more balanced.  Though 
it may seem counter-intuitive to remove the red blood cells and hence make the BLSS less 
biomimetic, in this case it improved the functionality of the device.  Use of whole blood in 
these devices can also be associated with problems due to leukocyte activation and cell 
damage (Allen et al., 2001).  An alternative to removing the red blood cells may be to 
increase the hepatocyte number and hence oxygen consumption in the device. This may 
necessitate redesigning of the hollow fibre bundle but may improve the efficacy of the 
device.  
 
The ELAD was also modelled using standard parameter values found in the literature.  An 
issue that must be addressed surrounding the C3A cell type is whether they exhibit the 
same response in terms of oxygen modulation as compared to primary hepatocytes, i.e. 
whether the zonation definitions above apply to them.  There is evidence that oxygen 
tension is a modulator of their expression of cytochrome P450 (Camp and Capitano, 2007).  
On this basis it is assumed here that the zonation profiles presented here are relevant to the 
C3A cell type but further research on the topic is necessary.  
 
Similar to the BLSS, the range of oxygen tensions under standard operating conditions in 
the ELAD appeared to be too high despite no red blood cells being present. This was the 
case even when using a lower inlet oxygen tension of 70 mmHg and is likely a result of the 
very high plasma flow rate being employed (500 ml/min) and the relatively short inter-
fibre distance of less than 50 µm. The procedure for optimizing the plasma flow rate in the 
ELAD was simpler than that for the previous two BALs.  The obvious step to take was to 
look at zonation profiles at a lower range of flow rate as the standard flow rate of 500 
ml/min was significantly greater than that seen previously in BAL applications.  Inlet 
oxygen tensions were set to either 70 or 90 mmHg as the available literature values did not 
make this value clear. In both cases, moderate plasma flow rates were found to produce 
evenly distributed zonation profiles. Similar to the BLSS, an alternative solution may be to 
increase the cell loading in the device to increase oxygen consumption in the device with 
Chapter 5: Modelling and Optimization of Commercial Bioartificial Liver Systems 
 118 
the added benefit of potentially greater efficacy. Also, it may be possible to partially 
fractionate the blood, i.e. use a proportion of the red blood cells to carry oxygen to the 
BAL rather than removing them entirely.  
 
In modelling the BALs described above, a number of assumptions had to be made over 
parameter values that have not been disclosed through recent literature or company 
websites. As such there is some uncertainty over how accurately the BALs have been 
portrayed here, for example the hollow fibre design in the HepaMate may be different to 
what has been assumed in this chapter. However, the broad characteristics of each system 
have been captured, for instance through the number and type of liver cells employed in 
each BAL.  Should more detailed information become available for each BAL, it would 
only require a small effort to update the models described here to reflect the new design 
parameters.  The utility of the mathematical framework developed over previous chapters 
has been illustrated here through application to specific BALs. Should the design of these 
BALs be different in reality, it would not diminish the ability of the framework to describe 
those same systems. 
 
5.5 Conclusions 
 
In previous chapters, a framework was established and developed to examine oxygen mass 
transport within hollow fibre-based BALs.  The implications of oxygenation on metabolic 
zonation and hence device functionality of the BAL were also established.  The lessons 
and techniques of these previous chapters have been taken and applied to three distinct 
privately-owned BAL designs that are currently progressing through various stages of 
clinical trials.  In each case, modelling results for each of the BALs have suggested that 
under current operating and design conditions oxygenation to the cells is in someway 
inadequate or non-ideal.  In the HepaMate it was concluded that the hollow fibre design 
was inappropriate and by changing it according to the lessons of Chapter 3 (i.e. a greater 
number of shorter, thinner fibres), oxygenation could be improved and well-balanced 
zonation profiles could be established. For the BLSS, it was deemed that by operating the 
device with patient plasma rather than whole blood allowed the zonation profiles to 
become balanced.  In the ELAD, simply reducing the plasma flow rate through the hollow 
fibre cartridges would be enough to improve the zone distribution.  These findings suggest 
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that in each of the BALs, consideration of the modelling results and the zonation 
physiological phenomenon can lead to more efficient and effective BALs. 
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Chapter 6: Discussion and Conclusions  
 
6.1 Discussion of findings 
 
In this section, the overall impact of this work will be considered in the context of the 
literature at present. In Chapter 2, an extensive review of literature relevant to BALs and 
modelling of such HFBR systems was performed. The functions and physiology of the 
human liver were studied and summarized to provide a context for liver support therapies. 
As the liver is such an important organ, the consequences of liver failure are often fatal 
with death rates being as high as 90% (Mareels et al., 2006, de Rave et al., 2002). The 
shortage of donor organs for the treatment of liver failure has spurred the growth of the 
liver support field.  This has encompassed devices such as the MARS and SPAD artificial 
livers (Stange et al., 1999, Peszynski et al., 2001) which each use albumin dialysis to 
detoxify blood, and BALs such as the BLSS and ELAD (Mazariegos et al., 2002, Sussman 
et al., 1991) which incorporate liver cells. As liver cells can potentially replace a wider 
range of liver functions and BALs have been more prevalent than their wholly artificial 
counterparts, it was decided to study these systems in particular. Much of the work on 
these systems in the past has been testing through pre-clinical (Patzer et al., 2002b) or 
small human trials (Ellis et al., 1996).  Undoubtedly, this work is important as many issues 
still surround the practicalities of BAL design (Section 2.2.3).  However, a mathematical 
modelling approach is more suitable to tackle fundamental issues over mass transport of 
nutrients to the cell population.  
 
Modelling work has been performed on BAL systems previously and numerous examples 
have been described. For example, Hay et al modelled previous versions of the ELAD and 
HepatAssist and examined whether sufficient oxygen was being delivered (Hay et al., 
2000, Hay et al., 2001).  However, one feature of the literature that is apparent is the lack 
of consideration over how modelling results may actually improve BAL design.  To date, 
modelling has generally been a tool for verification or otherwise of existing BAL or HFBR 
designs.  There is apparently little thought given towards how trends that can be identified 
from modelling can inform better designs. As a result, particular HFBRs are being 
employed in BALs with little rationale behind their choice.  This apparent gap in the 
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literature is what this work aims to address. This has been done primarily through the 
development of the Operating Region principle, where the results of a series of modelling 
simulations are collated and adapted to a graphical display. This method of data 
presentation allows quick visual verification of BAL designs and through comparison of 
various Operating Region charts, beneficial BAL design trends can be identified. For 
example, from looking at Operating Region charts constructed for hollow fibres of varying 
length, it became clear that the use of short fibres over fewer longer fibre resulted in a 
larger parameter space where the design constraints could be satisfied. As a result the BAL 
design has a greater protection against unforeseen deviations from the mathematical model.  
There has been no such claim in previous literature; rather the issue of hollow fibre 
geometry is largely ignored.  The value of the Operating Region charts in identifying these 
trends is clear; BAL designers now have a clear rationale for choosing particular HFBR 
designs over others. 
 
Another element of BAL design that is generally under-represented in the literature is the 
preservation of a physiological cell environment within the BAL.  While hollow fibres do 
have characteristics in common with capillary networks in the body, there otherwise seems 
to be little regard for biomimetic features in the BAL.  One aspect of liver physiology that 
can be carried over to BALs is that of zonation, where the gradient of oxygen tension along 
the liver sinusoids has a modulating effect on hepatocyte function.  In order to represent 
the full spectrum of liver functions within the BAL, the spectrum of oxygen tension in the 
BAL should closely match that in vivo. This has been explored in some modelling work as 
described in Section 2.3.5, but not in the sense of controlling zone distribution to create a 
more effective BAL.  For example, Sullivan et al have modelled oxygen mass transport 
and zonation in their own BAL design when the medium has been supplemented with 
oxygen carriers (Sullivan et al., 2007, Sullivan et al., 2008).  However, current literature 
lacks any detail over how zonation profiles can be manipulated through HFBR design and 
operating parameters. In this work, the range of possible zone distributions while 
remaining within the bounds of the Operating Region was explored.  It was found that zone 
profiles could be predicted and therefore controlled in BALs. In certain cases each 
metabolic zone could be made to occupy the same fraction of the cell mass.  This presents 
the BAL designer with the potential to improve device functionality through maintenance 
of the correct oxygen gradients in the system. 
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This work has developed tools to improve and optimize the designs of BALs.  Where the 
literature once was sparse on rationales for choosing particular HFBR designs and 
operating parameters, this report has filled the void.  As an example of this potential, the 
principles of the Operating Region and zonation were applied to commercial BAL designs, 
each one currently in various stages of the clinical trial process. In each case, it was found 
that the designs could be improved and indeed optimized with regard to oxygen delivery. 
Surprisingly, it appeared that both the BLSS and the ELAD were over-oxygenating their 
respective cell masses in that the oxygen tensions were above in vivo levels. Literature has 
generally focussed on the limitations of hollow fibres in supplying oxygen; it was 
unexpected that in these cases too much oxygen was being delivered. This is a new 
discovery that has not yet been reported in literature, underlining how tangible and 
important benefits to BAL design can be gleaned through application of the methods 
developed here.  Ultimately, adoption of these principles can hasten the transition of BAL 
technology from a concept to a real clinical device which can save the lives of many 
people. 
 
6.2 Conclusions 
 
This work has examined one of the major technical hurdles in BAL design, namely the 
mass transport of oxygen. Faced with this issue, the answer was to develop a framework to 
rationalize and optimize the choice of design parameters for BALs.  
 
The first step taken towards this goal was to develop a mathematical model based to 
describe the mass transport of oxygen within a BAL, as seen in Chapter 3. The model 
assumed Krogh cylinder geometry, i.e. that through symmetry of a perfectly straight array 
of hollow fibres that do not interact, it is sufficient to model one representative sub-unit to 
describe the whole fibre bundle. The model also incorporates features typical in the field 
such as a Poisueille flow profile in the fibre lumen and Michaelis-Menten reaction kinetics 
to describe oxygen uptake by the cells.   In order to solve the model equations, the finite 
element-based software COMSOL was employed.  By using software, arrays of modelling 
solutions could be produced by sequentially varying parameter values, such as plasma flow 
rates or fibre length and radius.  
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In order to represent the modelling data in a meaningful way, a constraint representing the 
minimum required supply of oxygen was defined as a function of the model solutions. A 
further constraint representing the minimum required cell number was also identified and 
defined as a function of the HFBR design parameters. The definitions of each constraint 
allowed them to be represented graphically, hence producing the Operating Region chart.  
The Operating Region chart displays a parameter space where the BAL operating 
constraints can be satisfied simultaneously, allowing visual verification of particular BAL 
set-ups. In addition to this, through varying parameters such as fibre length and radius, 
plasma flow rate and cell number, beneficial design trends could be identified. Importantly, 
the results also showed that therapeutically relevant cell volumes of between 10-20% of 
the adult liver cell mass could be supported in the BAL. 
 
To further develop the usefulness of the Operating Region principle, greater consideration 
of liver physiology was incorporated into the mathematical model in Chapter 4.  In 
particular this concerned applying definitions of metabolic zonation to the BAL cell mass 
where local oxygen tensions delineate each zone.  If the BAL is to function in a similar 
manner to the native liver, it was hypothesized that the range of oxygen tensions should 
closely match that seen in vivo. Modelling parameters were varied to ascertain their 
importance in influencing the distribution of the metabolic zones in the cell mass.  It was 
found that fibre geometry did not have a strong influence over the distribution of the zones, 
whereas parameters such as inlet oxygen tension, plasma flow rate, cell number and 
maximal oxygen uptake rate were important factors.  It was also found that a double cell 
layer model also made it more difficult to evenly distribute the zones compared to a single 
cell layer.  Under certain conditions, e.g. where the cells have a relatively low oxygen 
uptake rate, it was shown that it is possible to over oxygenate the cells.  In this situation the 
zonation profile is skewed towards the periportal zone, possible leading to reduced BAL 
functionality. This situation has to date not been examined in literature, where traditionally 
it has been assumed oxygen mass transport is limited in HFBR cell culture applications. In 
addition to examining the importance of the modelling parameters in determining the zone 
distribution profiles, the flow rates and cell numbers that would result in evenly distributed 
profiles were also ascertained.  Although it cannot be confirmed that equal zone sizes 
represent the optimum situation in the BAL, Chapter 4 demonstrates that through careful 
choice of the design parameters it is possible to control zone sizes to particular 
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specifications. This has the potential to improve BAL efficacy through mimicry of the 
physiological cell environment. 
 
Chapters 3 and 4 have established a framework for evaluating BALs in terms of oxygen 
supply and liver cell function for general designs, i.e. to first determine the parameter 
space where the operating constraints of BALs can be satisfied and then optimize the 
design through consideration of zonation profiles.  These principles were applied to 
examples of existing BALs, through some modifications to the mathematical model.  
Initially, each of the example BALs operating under normal conditions were modelled 
using parameters obtained from literature or otherwise assumed.   It was clear in each case 
that oxygenation was non-ideal; regions of anoxia were present in the HepaMate while the 
cell mass appeared to be over-oxygenated in the ELAD and BLSS.  Unbalanced metabolic 
zones would result in each of these BALs as a consequence, potentially hampering their 
functionality. For each BAL, the optimal plasma or blood flow rate was found to balance 
the zones but this proved to be ineffective for the HepaMate and BLSS. In each of these 
cases the BAL design was altered to achieve balanced zonation profiles; the fibre design 
was modified for the former and the red blood cells separated from the plasma in the case 
of the latter.  The work in Chapter 5 demonstrated the utility of the mathematical 
framework developed in the previous chapters by diagnosing mass transport issues in each 
of the BALs and in theory, being able to remedy them.  
 
In this work, the fundamental issues regarding mass transport to the liver cells and their 
corresponding metabolic behaviour have been considered.  HFBRs have been used 
extensively in BALs though have been hampered through deficient oxygen supply to the 
cell mass.  The techniques and findings disseminated here have sought to link HFBR 
design and operating parameters to oxygen supply to aid BAL designers who previously 
had no rationale for choosing a bioreactor design. In the first instance, Operating Region 
charts can be constructed for various BAL configurations to allow rapid and simple 
verification. The design can then be optimized with regards to the desired zonation profile 
to maximize its therapeutic potency. It is hoped that through this work the next generation 
of BALs can successfully make the transition from a concept to a clinical reality, where 
countless lives can be saved. 
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6.3 Future Work 
 
The work presented here is novel and important to the design of future generations of 
BALs.  However, there are further steps that can be taken to build on this work and 
increase its relevance.  The main component to be added is comprehensive physical, 
experimental data that can further validate the model employed to describe the BALs.  In 
particular, the oxygen consumption rate is a vital parameter in determining the 
characteristics of the BAL (Catapano and DeBartolo, 1996).  Identifying this parameter 
would involve seeding cells into the ECS of a hollow fibre bioreactor and measuring 
oxygen uptake under various conditions.  A method based on the one outlined by Mishra 
and Starly (2009) could be employed,  where fibre optic sensors are used to measure 
oxygen levels in real time within alginate matrices containing a liver cell line.  
Alternatively, magnetic resonance imaging techniques have been used to determine 
dissolved oxygen levels in hollow fibre bioreactors (Williams et al., 1997) and could be 
utilised here.  Michaelis-Menten parameters could then be estimated by fitting the model 
solution to experimental data.   
 
Additional features can be added to the modelling, for example the use of artificial oxygen 
carriers in the plasma stream. This would allow a greater amount of oxygen to be carried 
by the plasma and possibly improve the range of viable BAL designs while also offering 
greater flexibility over the metabolic zone distribution.  The use of the oxygen carrier 
perfluorocarbon (PFC) in BALs has been studied by Kinasiewicz et al (2008b). They found 
that C3A cells had increased protein synthesis rates when the medium was supplemented 
with PFC.   PFC has been used to deliver oxygen in other tissue engineering applications 
such as cardiac tissue engineering (Radisic et al., 2005). 
 
An approach used extensively in this work and in hollow fibre modelling in general is the 
Krogh cylinder representation.  It is favoured over other approaches as it transforms a 
fundamentally complicated system consisting of thousands of individual fibres into a 
relatively simple model.  However, a number of the assumptions made to do this are not 
realistic. For example, the assumption that all the fibres are perfectly straight and arranged 
in a hexagonal pattern (Fig. 2.10) does not hold in practice.  As a result the assumption that 
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the mass transport profiles of each fibre do not interact is also invalid.  The Krogh cylinder 
approach is certainly useful and experimentally-validated models based on it do exist, 
however perhaps a future direction may be to examine other modelling strategies.  One 
example may be the porous medium model developed by Labecki et al. (1995). This model 
treats the ECS and hollow fibres as interpenetrating porous regions which allows the 
interchange of fluid and solutes.  This model removes the need to assume regularly spaced, 
identical fibres and has been used to describe protein transport in HFBRs (Labecki et al., 
2004, Labecki et al., 1996). It does require modification to describe diffusive transport of 
small molecules such as oxygen however.  An alternative modification to the Krogh 
cylinder model may be to employ techniques developed by Sardonini and DiBiasio 
(Sardonini and DiBiasio, 1992, Sardonini and DiBiasio, 1993). In this model, the position 
of the hollow fibres in the cartridge is randomly generated. Using numerical and statistical 
methods, the resulting cell density profiles could be found.  This adds a layer of 
complexity to the model, but may be hard to scale-up to BALs containing thousands of 
fibres. Application of some of these principles may lead to interesting developments in 
BAL design. 
 
Outside the scope of BALs, the techniques developed in this work can also be applied in 
other fields.  Mass transport is a significant issue for any hollow fibre bioreactor 
application due to the membrane separation of cells and medium.  Within tissue 
engineering, hollow fibre bioreactors are used to grow tissues such as bone (Morgan et al., 
2007, Ellis and Chaudhuri, 2007, Ye et al., 2006) and or as the basis of a bioartificial 
pancreas (Dulong and Legallais, 2007, Pillarella and Zydney, 1990) or kidney (Saito, 
2003). In each case it is feasible to employ the Operating Region approach to guide 
optimization of hollow fibre design. Outside of tissue engineering, biofilms are grown on 
hollow fibre surfaces for various applications such as nitric oxide removal from waste 
gases (Kumar et al., 2010) or treatment of wastewater (Beyenal and Tanyolac, 1994). The 
Operating Region concept could also be applied in these instances. 
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Appendix 
A.1 Matlab Scripting 
A.1.1 Zonation profile script 
function [Z2 Z10 Z25 Z35 Z60 Z70] = hollowfibreBAL(pO2_inlet, Vmax, 
Cell_layers, membrane_thickness) %returns boundary positions for 
particular BAL set-ups 
Z2=[]; % define arrays which hold the axial positions of the relevant 
zone boundaries 
Z10=[]; 
Z25=[]; 
Z35=[]; 
Z60=[]; 
Z70=[]; 
w = membrane_thickness; 
pO2 = pO2_inlet; 
CL = Cell_layers; 
    for ubar = 1e-3:1.5e-3:7e-3 %loop through the range of plasma flow 
rates, finding the zonation profile in each case 
        Rl = 1.4e-4; 
        Rm = Rl+w; 
        Rk = Rl+w+CL*25e-6; 
 
 
        % COMSOL Multiphysics Model M-file 
        % Generated by COMSOL 3.5a (COMSOL 3.5.0.606, $Date: 2009/04/29 
09:11:29 $) 
 
        flclear fem 
 
        % COMSOL version 
        clear vrsn 
        vrsn.name = 'COMSOL 3.5'; 
        vrsn.ext = 'a'; 
        vrsn.major = 0; 
        vrsn.build = 606; 
        vrsn.rcs = '$Name: v35ap $'; 
        vrsn.date = '$Date: 2009/04/29 09:11:29 $'; 
        fem.version = vrsn; 
 
 
        % Constants 
        fem.const = {'ubar',ubar, ... 
            'Rl', Rl ... 
           'Vmax',Vmax}; 
 
        % Geometry 
        g1=rect2(Rl,1e-3/CL,'base','corner','pos',{'0','0'},'rot','0'); 
        g2=rect2(Rm,1e-3/CL,'base','corner','pos',{'0','0'},'rot','0'); 
        g3=rect2(Rk,1e-3/CL,'base','corner','pos',{'0','0'},'rot','0'); 
 
        % Analyzed geometry 
        clear s 
        s.objs={g1,g2,g3}; 
        s.name={'R1','R2','R3'}; 
        s.tags={'g1','g2','g3'}; 
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        fem.draw=struct('s',s); 
        fem.geom=geomcsg(fem); 
 
        % Initialize mesh 
        fem.mesh=meshinit(fem, ... 
                          'hauto',5); 
 
        % Refine mesh 
        fem.mesh=meshrefine(fem, ... 
                            'mcase',0, ... 
                            'rmethod','regular'); 
        fem.mesh=meshrefine(fem, ... 
                            'mcase',0, ... 
                            'rmethod','regular'); 
 
        % (Default values are not included) 
 
        % Application mode 1 
        clear appl 
        appl.mode.class = 'ConvDiff'; 
        appl.mode.type = 'axi'; 
        appl.module = 'CHEM'; 
        appl.sshape = 2; 
        appl.assignsuffix = '_chcd'; 
        clear prop 
        prop.analysis='static'; 
        appl.prop = prop; 
        clear bnd 
        bnd.c0 = {0,0,pO2,0,0}; 
        bnd.type = {'N0','cont','C','ax','Nc'}; 
        bnd.ind = [4,3,5,2,1,1,2,1,1,1]; 
        appl.bnd = bnd; 
        clear equ 
        equ.dtensor = {{{3e-9;0}},{{3e-9;0}},{{2e-9;0}}}; 
        equ.v = {'2*ubar*(1-(r/Rl)^2)/1000',0,0}; %Poisueille flow in 
lumen 
        equ.R = {0,0,'-481*Vmax*c/(c+3)'}; %Michaelis-Menten kinetics 
        equ.dtype = 'aniso'; 
        equ.ind = [1,2,3]; 
        appl.equ = equ; 
        fem.appl{1} = appl; 
        fem.sdim = {'r','z'}; 
        fem.frame = {'ref'}; 
        fem.border = 1; 
        fem.outform = 'general'; 
        clear units; 
        units.basesystem = 'SI'; 
        fem.units = units; 
 
        % ODE Settings 
        clear ode 
        clear units; 
        units.basesystem = 'SI'; 
        ode.units = units; 
        fem.ode=ode; 
 
        % Multiphysics 
        fem=multiphysics(fem); 
 
        % Extend mesh 
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        fem.xmesh=meshextend(fem); 
 
        % Solve problem 
        fem.sol=femstatic(fem, ... 
              'solcomp',{'c'}, ... 
              'maxiter',40, ... 
              'outcomp',{'c'}); 
 
        % Save current fem structure for restart purposes 
        fem0=fem; 
 
 
        % Find position of each zone boundary 
        [m2 d2] = postmin(fem,'sqrt((c-2)^2)','edim',1,'dl',10); 
        Z2(:,end+1)=d2(2)*1000; 
        [m10 d10] = postmin(fem,'sqrt((c-10)^2)','edim',1,'dl',10); 
        Z10(:,end+1)=d10(2)*1000; 
        [m25 d25] = postmin(fem,'sqrt((c-25)^2)','edim',1,'dl',10); 
        Z25(:,end+1)=d25(2)*1000; 
        [m35 d35] = postmin(fem,'sqrt((c-35)^2)','edim',1,'dl',10); 
        Z35(:,end+1)=d35(2)*1000; 
        [m60 d60] = postmin(fem,'sqrt((c-60)^2)','edim',1,'dl',10); 
        Z60(:,end+1)=d60(2)*1000; 
        [m70 d70] = postmin(fem,'sqrt((c-70)^2)','edim',1,'dl',10); 
        Z70(:,end+1)=d70(2)*1000; 
    end 
 
A.1.2 Optimization script 
   
function [Qopt1 optimal_zone_pattern1 Qopt2 optimal_zone_pattern2 ] = 
HepaMate_optimum  
%Return flowrates and zonation pattern for each optimization protocol 
  
  
% COMSOL Multiphysics Model M-file 
% Generated by COMSOL 3.5a (COMSOL 3.5.0.606, $Date: 2009/04/29 09:11:29 
$) 
  
flclear fem 
Ncell=1.4e10; 
Nf=4800; 
Rl=1.6e-4; 
Rm=1.9e-4; 
L=.25; 
Dl=3e-9; 
Lz = []; 
L70 =[]; 
L60 =[]; 
L35 =[]; 
L25 =[]; 
L10 =[]; 
L2=[]; 
epsilon = 0.5; 
De=epsilon*2e-9+(1-epsilon)*Dl;  
Vecs_per_fibre=Ncell*(4/3)*(3.142*12.5e-6^3)/(Nf*epsilon); 
Re=sqrt((Vecs_per_fibre+Rm^2*3.142*L)/(3.142*L));  
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for ubar = 
(250/6e7/Nf)/(3.142*Rl^2):(5/6e7/Nf)/(3.142*Rl^2):(400/6e7/Nf)/(3.142*Rl^
2); %Scan through range of flowrates, 250-400 ml/min     
    % COMSOL version 
    clear vrsn 
    vrsn.name = 'COMSOL 3.5'; 
    vrsn.ext = 'a'; 
    vrsn.major = 0; 
    vrsn.build = 606; 
    vrsn.rcs = '$Name: v35ap $'; 
    vrsn.date = '$Date: 2009/04/29 09:11:29 $'; 
    fem.version = vrsn; 
  
    % Constants 
    fem.const = {'Dl',Dl, ... 
      'De',De, ... 
      'Vmax','5.87e-3 [mol/s/m^3]', ... 
      'Km','3 [mmHg]', ... 
      'epsilon',epsilon, ... 
      'Rl',Rl, ... 
      'Rm',Rm, ... 
      'Re',Re, ... 
      'ubar',ubar, ... 
      'pO2_inECS','80' ... 
      'L',L, ... 
      'alpha','2.08e-3', ... 
      'pO2_in','90', ... 
      'pO2min','10', ... 
      'Dm','3e-9'}; 
  
    % Geometry 
    g1=rect2('1','1','base','corner','pos',{'0','0'},'rot','0'); 
    g2=rect2(Rm/Rl,'1','base','corner','pos',{'0','0'},'rot','0'); 
    g3=rect2(Re/Rl,'1','base','corner','pos',{'0','0'},'rot','0'); 
  
    % Analyzed geometry 
    clear s 
    s.objs={g1,g2,g3}; 
    s.name={'R1','R2','R3'}; 
    s.tags={'g1','g2','g3'}; 
  
    fem.draw=struct('s',s); 
    fem.geom=geomcsg(fem); 
  
    % Initialize mesh 
    fem.mesh=meshinit(fem, ... 
                      'hauto',5); 
  
    % Refine mesh 
    fem.mesh=meshrefine(fem, ... 
                        'mcase',0, ... 
                        'rmethod','regular'); 
  
    % Refine mesh 
    fem.mesh=meshrefine(fem, ... 
                        'mcase',0, ... 
                        'rmethod','regular'); 
  
    % Refine mesh 
    fem.mesh=meshrefine(fem, ... 
                        'mcase',0, ... 
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                        'rmethod','regular'); 
  
  
    % (Default values are not included) 
  
    % Application mode 1 
    clear appl 
    appl.mode.class = 'FlConvDiff'; 
    appl.mode.type = 'axi'; 
    appl.dim = {'pO2'}; 
    appl.sshape = 2; 
    appl.assignsuffix = '_cd'; 
    clear prop 
    prop.analysis='static'; 
    appl.prop = prop; 
    clear bnd 
    bnd.c0 = {0,0,'pO2_in',0,0}; 
    bnd.type = {'N0','cont','C','Nc','ax'}; 
    bnd.ind = [5,3,4,2,1,1,2,1,1,1]; 
    appl.bnd = bnd; 
    clear equ 
    equ.init = {'pO2_in',0,0}; 
    equ.dtensor = 
{{{'Dl/Rl^2';'Dl/L^2'}},{{'Dm/Rl^2';'Dm/L^2'}},{{'De/Rl^2';'De/L^2'}}}; 
    equ.v = {'2*ubar*(1-r^2)/L',0,0}; 
    equ.R = {0,0,'-epsilon*Vmax*pO2/(alpha*(pO2+Km))'}; 
    equ.dtype = 'aniso'; 
    equ.ind = [1,2,3]; 
    appl.equ = equ; 
    fem.appl{1} = appl; 
    fem.sdim = {'r','z'}; 
    fem.frame = {'ref'}; 
    fem.border = 1; 
    fem.outform = 'general'; 
  
    % Descriptions 
    clear descr 
    descr.const= {'alpha','henry constant','X','Hb fraction'}; 
    descr.globalexpr= {'Seq','equilibrium 
saturation','RHbO2','binding/release kinetics'}; 
    fem.descr = descr; 
  
    % Multiphysics 
    fem=multiphysics(fem); 
  
    % Extend mesh 
    fem.xmesh=meshextend(fem); 
  
    % Solve problem 
    fem.sol=femstatic(fem, ... 
                      'solcomp',{'pO2'}, ... 
                      'outcomp',{'pO2'}, ... 
                      'maxiter',40, ... 
                      'blocksize','auto'); 
  
    % Save current fem structure for restart purposes 
    fem0=fem; 
  
         [m z] = postmin(fem,'sqrt((pO2-70)^2)','edim',1,'dl',10); 
         L70(end+1)=L*z(2); 
         [m2 z2] = postmin(fem,'sqrt((pO2-60)^2)','edim',1,'dl',10); 
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         L60(end+1)=L*z2(2); 
         [m3 z3] = postmin(fem,'sqrt((pO2-35)^2)','edim',1,'dl',10); 
         L35(end+1)=L*z3(2); 
         [m4 z4] = postmin(fem,'sqrt((pO2-25)^2)','edim',1,'dl',10); 
         L25(end+1)=L*z4(2); 
         [m5 z5] = postmin(fem,'sqrt((pO2-10)^2)','edim',1,'dl',10); 
         L10(end+1)=L*z5(2); 
         [m6 z6] = postmin(fem,'sqrt((pO2-2)^2)','edim',1,'dl',10); 
         L2(end+1)=L*z6(2); 
  
end 
Lz = [L70',L60',L35',L25',L10']; 
zones=[L70/L,(L60-L70)/L,(L35-L60)/L,(L25-L35)/L,(L10-L25)/L,(L-L10)/L]; 
Lz = [L70',L60',L35',L25',L10']; 
zones=[L70/L;(L60-L70)/L;(L35-L60)/L;(L25-L35)/L;(L10-L25)/L;(L-L10)/L]'; 
x=zones(:,1)+zones(:,2); 
y=zones(:,4)+zones(:,5); 
zopt=sqrt((((L60-L70)/L)-((L25-L35)/L)).^2); %optimize by setting 
periportal=perivenous 
zopt2=sqrt((x-y).^2);  %optimize by setting hyper+periportal = 
perivenous+hypo 
[C I]=min(zopt); 
while L10(I)<L %scan through all zonation profiles, finding the optimum 
    zopt(I)=10; 
    [C I]=min(zopt);  
end 
[C2 I2]=min(zopt2); 
while L10(I2)<L 
    zopt2(I2)=10; 
    [C2 I2]=min(zopt2); 
end 
ubar = 
(250/6e7/Nf)/(3.142*Rl^2):(5/6e7/Nf)/(3.142*Rl^2):(400/6e7/Nf)/(3.142*Rl^
2); 
optimal_zone_pattern1 = zones(I,:); 
optimal_zone_pattern2 = zones(I2,:); 
Qopt1 = 6e7*3.142*Rl^2*Nf*ubar(I); 
Qopt2 = 6e7*3.142*Rl^2*Nf*ubar(I2); 
 
Similar scripts exist for the optimization of the BLSS and ELAD systems. 
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